🏷

Classifications

Harrison's Part

◆

Subtypes

4

Heterozygous Familial Hypobetalipoproteinemia 1 (APOB) MONDO:0014252

APOB hgnc:603 Semidominant inheritance

Heterozygous carriage of one APOB truncating (nonsense, frameshift, or canonical splice-site) allele. Usually identified incidentally through low LDL cholesterol on routine lipid panels and is frequently asymptomatic biochemically, though hepatic steatosis and mild transaminase elevation are the main clinical manifestations because the truncated apoB variant is co-produced with the normal allele's product and can accumulate in hepatocytes even as less apoB-lipoprotein reaches plasma.

Homozygous or Compound Heterozygous Familial Hypobetalipoproteinemia 1 (APOB) MONDO:0014252

APOB hgnc:603 Autosomal recessive inheritance

Two APOB truncating alleles (homozygous or compound heterozygous), producing a severe phenotype that closely mimics abetalipoproteinemia: very low or absent apoB-containing lipoproteins, gastrointestinal and neurologic dysfunction, fat-soluble-vitamin deficiency, hepatomegaly, and steatorrhea. GeneReviews classifies the biallelic-caused disease itself as autosomal recessive, distinct from the codominant biochemical trait seen in single-allele carriers.

PCSK9 Loss-of-Function Hypobetalipoproteinemia

PCSK9 hgnc:20001 Autosomal dominant inheritance

Heterozygous PCSK9 nonsense or loss-of-function missense variants reduce or abolish PCSK9-mediated degradation of the hepatic LDL receptor, increasing receptor recycling and hepatic LDL clearance. Unlike FHBL1, this is a clearance-enhancement rather than a production-limiting mechanism, is not associated with hepatic steatosis or fat malabsorption, and is clinically benign and cardioprotective; it is the human-genetics basis for PCSK9-inhibitor therapy.

ANGPTL3-Related Familial Combined Hypolipidemia (FHBL2) MONDO:0011505

ANGPTL3 hgnc:491 Autosomal recessive inheritance

Biallelic ANGPTL3 loss-of-function variants abolish ANGPTL3-mediated inhibition of lipoprotein lipase and endothelial lipase, increasing catabolism of triglyceride-rich lipoproteins. Because ANGPTL3 normally restrains clearance of VLDL, LDL, and HDL alike, its complete loss produces a combined hypolipidemia affecting all three lipoprotein classes rather than a selective LDL/apoB defect, distinguishing it from FHBL1 and PCSK9 loss of function. GeneReviews reports the syndrome as clinically silent - "not associated with any pathologic signs or symptoms" - and, like PCSK9 loss of function, it is not associated with hepatic steatosis. It is the mechanistic basis for ANGPTL3-inhibitor (evinacumab) therapy.

?

Discussions and Knowledge Gaps

1

Beyond APOB, PCSK9, and ANGPTL3, what is the causal gene for the hypobetalipoproteinemia families linked to a chromosome 3p21 susceptibility locus, and for the additional families linked to neither APOB nor 3p21?

KNOWLEDGE GAP OPEN gap_fhbl_non_apob_locus

Attached to

pathophysiology#Reduced Circulating ApoB-Containing Lipoprotein Concentration

This entry curates three molecularly resolved causal genes, but the literature independently documents at least one additional linked locus (chromosome 3p21) and further families with hypobetalipoproteinemia linked to neither APOB nor that locus, whose causal gene(s) remain unidentified. Unlike heterozygous APOB-FHBL1, the chromosome 3p21-linked form does not have increased liver fat, so it is not simply a phenocopy of the production-limited APOB route and may represent a fourth distinct mechanism.

Proposed experiments

Positional cloning / whole-genome sequencing of chromosome 3p21-linked FHBL families

fhbl_3p21_positional_cloning

Apply whole-genome or long-read sequencing to pedigrees with linkage to chromosome 3p21 (and to families linked to neither APOB nor 3p21) to identify the causal gene(s) and determine whether they act by a production-limiting, clearance-enhancing, or novel mechanism.

Show evidence (3 references)

PMID:15818469 SUPPORT Other

"Three genetic forms exist: (i) premature stop codon specifying mutations of APOB; (ii) FHBL linked to a susceptibility locus on the chromosome 3p21; and (iii) FHBL linked neither to APOB nor to the chromosome 3p21."

States that molecularly uncharacterized non-APOB FHBL loci exist independent of the genes curated in this entry.

PMID:15818469 SUPPORT Other

"Liver fat in the chromosome 3p21-linked FHBL is normal."

Shows the 3p21-linked form does not share the hepatic steatosis mechanism curated for the APOB route, arguing it is mechanistically distinct rather than a minor variant.

PMID:20942659 SUPPORT Human Clinical

"Significant lod scores were not found for regions on chromosomes 3 and 10 previously reported to be associated with familial hypobetalipoproteinemia,6,7 nor for any other regions in the genome."

Independently corroborates that FHBL families exist that map to loci other than APOB, PCSK9, or ANGPTL3.

⚙

Pathophysiology

13

APOB Truncating Variant

A nonsense, frameshift, or canonical splice-site variant in APOB truncates the apoB open reading frame, producing a shortened apoB protein (apoB-XX nomenclature, denoting the percentage of full-length apoB translated) instead of full-length apoB-100/apoB-48. Over 60 distinct truncating APOB mutations, ranging from apoB-2 to apoB-89, have been reported as causes of FHBL1.

APOB hgnc:603

Genetic context APOB hgnc:603 variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION

A truncating allele produces less protein and/or a protein that assembles and secretes lipoprotein particles less efficiently than full-length apoB - a straightforward loss-of-function call, in contrast to the partial, conformational loss-of-function of the ligand-binding-region missense alleles curated in Familial_Defective_Apolipoprotein_B-100.yaml.

Downstream

Impaired Hepatic and Intestinal ApoB-Lipoprotein Assembly and Secretion Truncated apoB is produced in reduced quantity and is secreted far less efficiently than the predicted 50% gene-dosage share.

Show evidence (1 reference)

PMID:24751931 SUPPORT Other

"Over 60 mutations producing truncations in the apoB gene ranging from apoB2 to apoB-89 have been identified as causes of FHBL"

Documents the range of truncating APOB alleles causing FHBL1.

Impaired Hepatic and Intestinal ApoB-Lipoprotein Assembly and Secretion

Truncated apoB reduces the pool of apoB-lipoprotein particles available for hepatic VLDL and intestinal chylomicron assembly and secretion, a production-limited mechanism distinct from the lipidation defect of abetalipoproteinemia. Kinetic studies attribute the disproportionately low heterozygous apoB levels to markedly reduced VLDL apoB-100 secretion, decreased LDL apoB-100 production, increased VLDL catabolism, and extremely low secretion of the truncated species itself.

hepatocyte CL:0000182 enterocyte CL:0000584

very-low-density lipoprotein particle assembly GO:0034379 ↓ DECREASED

Animal models

Apob-38.9 heterozygous mouse (FHBL1 model) Mouse recapitulates Apob-38.9 heterozygous mice reproduce the disproportionate (well beyond the 50% gene-dosage expectation) reduction in hepatic apoB-100 secretion documented in human heterozygous FHBL1, and localize the defect in vivo and in primary hepatocytes to a secretion step rather than reduced synthesis from the intact allele.

Downstream

Reduced Circulating ApoB-Containing Lipoprotein Concentration Fewer apoB-lipoprotein particles are secreted into plasma.

Hepatic Triglyceride Retention Reduced hepatic apoB secretion decreases triglyceride export from the liver in VLDL, producing hepatic steatosis even as less apoB-lipoprotein reaches plasma.

Show evidence (1 reference)

PMID:24751931 SUPPORT Human Clinical

"these lower than expected levels result from a 74% lower secretion rate of VLDL apoB-100 from the liver, decreased production of LDL apoB-100, increased catabolism of VLDL and extremely low secretion of the truncated apoB"

Kinetic evidence directly establishes the reduced hepatic secretion mechanism.

Hepatic Triglyceride Retention

Reduced hepatic VLDL export retains triglyceride within hepatocytes, producing hepatic steatosis that can progress to steatohepatitis, fibrosis, and rarely cirrhosis or hepatocellular carcinoma, even in heterozygous carriers. This hepatic-storage consequence is characteristic of the APOB production-limited route and is not seen with the PCSK9 or ANGPTL3 clearance-enhanced routes.

hepatocyte CL:0000182

lipid storage GO:0019915 ↑ INCREASED

Downstream

Hepatic steatosis Hepatocyte triglyceride retention is observed as hepatic steatosis.

Cirrhosis Chronic hepatic triglyceride accumulation can progress to steatohepatitis and, rarely, cirrhosis or hepatocellular carcinoma, even in individuals with only a heterozygous truncating allele.

Show evidence (1 reference)

PMID:24751931 SUPPORT Human Clinical

"In 32 subjects with FHBL, average hepatic fat content measured by MR spectroscopy was 14.8% + 12.0% compared to 5.2% + 5.9%, respectively, for 33 normolipidemic controls"

Directly measures increased hepatic fat content in FHBL subjects compared to matched controls.

PCSK9 Loss-of-Function Variant

A PCSK9 nonsense or loss-of-function missense variant reduces or abolishes secreted PCSK9 activity. First identified through sequencing of PCSK9 in subjects with low plasma LDL specifically to test whether loss-of-function variants would have the mirror-image effect of the gain-of-function PCSK9 variants that cause autosomal dominant hypercholesterolemia (kb/disorders/Autosomal_Dominant_Hypercholesterolemia_3.yaml).

PCSK9 hgnc:20001

Genetic context PCSK9 hgnc:20001 variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION

The mirror-image lesion class to the gain-of-function PCSK9 missense variants that cause autosomal dominant hypercholesterolemia type 3 (ADH3): here, nonsense or loss-of-function missense variants reduce or abolish PCSK9 protease activity rather than enhancing it.

Downstream

Reduced PCSK9-Mediated LDL Receptor Degradation Loss of PCSK9 function removes the normal restraint on hepatic LDL receptor turnover.

Show evidence (1 reference)

PMID:15654334 SUPPORT Human Clinical

"To test whether loss-of-function mutations in PCSK9 have the opposite effect, we sequenced the coding region of PCSK9 in 128 subjects (50% African American) with low plasma levels of LDL and found two nonsense mutations (Y142X and C679X)"

The discovery study explicitly frames these as loss-of-function variants, the mirror image of the known gain-of-function hypercholesterolemia alleles.

Reduced PCSK9-Mediated LDL Receptor Degradation

PCSK9 normally binds the hepatic LDL receptor and directs it toward lysosomal degradation after endocytosis rather than recycling it to the cell surface. Loss-of-function PCSK9 variants remove this restraint, so more LDL receptor recycles back to the hepatocyte surface. This is the exact mechanistic node that PCSK9-inhibitor biologics (evolocumab, alirocumab) pharmacologically reproduce to lower LDL cholesterol in hypercholesterolemia.

hepatocyte CL:0000182

low-density lipoprotein particle receptor catabolic process GO:0032802 ↓ DECREASED

Downstream

Increased Hepatic LDL Receptor Density Reduced receptor degradation increases steady-state hepatic LDL receptor abundance available for uptake.

Show evidence (1 reference)

PMID:24751931 SUPPORT Other

"PCSK9 is a secreted serine protease that enhances the degradation of the LDL-receptor. Loss of function mutations in the PCSK9 gene prevent the PCSK9-mediated degradation of the LDL receptor and thus increase uptake of LDL by the liver, a process leading to a 30 to 70% reduction in plasma LDL-C levels"

States both the normal PCSK9 mechanism and the quantitative effect of its loss on plasma LDL cholesterol.

Increased Hepatic LDL Receptor Density

More LDL receptor is available at the hepatocyte surface for receptor-mediated uptake of circulating LDL, increasing hepatic clearance of apoB-containing lipoproteins from plasma.

hepatocyte CL:0000182

liver UBERON:0002107

Downstream

Reduced Circulating ApoB-Containing Lipoprotein Concentration Enhanced hepatic LDL-receptor-mediated uptake increases clearance of circulating LDL, unlike the production-limited APOB route.

ANGPTL3 Loss-of-Function Variant

Biallelic ANGPTL3 loss-of-function variants (compound heterozygous or homozygous nonsense/frameshift alleles) abolish secreted ANGPTL3 activity. Discovered by whole-exome sequencing of two siblings with combined hypolipidemia not linked to APOB.

ANGPTL3 hgnc:491

Genetic context ANGPTL3 hgnc:491 variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION

Nonsense and frameshift alleles that abolish secreted ANGPTL3 protein; the LDL-cholesterol and triglyceride phenotypes are gene-dosage dependent (codominant) while the HDL-cholesterol phenotype requires biallelic loss (recessive), a within-locus dissociation of inheritance mode by trait.

Downstream

Loss of ANGPTL3-Mediated Lipase Inhibition Loss of ANGPTL3 removes its normal inhibitory restraint on lipoprotein lipase and endothelial lipase.

Show evidence (1 reference)

PMID:20942659 SUPPORT Human Clinical

"These two participants were compound heterozygotes for two distinct nonsense mutations in ANGPTL3 (encoding the angiopoietin-like 3 protein)."

The discovery study identifies the causal ANGPTL3 nonsense mutations by exome sequencing.

Loss of ANGPTL3-Mediated Lipase Inhibition

ANGPTL3 normally inhibits lipoprotein lipase and endothelial lipase, the key enzymes that hydrolyze circulating triglyceride-rich lipoproteins and HDL, respectively. Loss of ANGPTL3 function increases the activity of both enzymes. This is the established mechanism for the triglyceride and HDL-cholesterol reductions; the mechanism by which ANGPTL3 deficiency also lowers LDL cholesterol is less well resolved (see mechanism_confidence below).

lipoprotein lipase activity GO:0004465 ↑ INCREASED

Downstream

Enhanced Catabolism of Triglyceride-Rich Lipoproteins Increased lipase activity accelerates lipolytic catabolism of VLDL and HDL; the LDL branch is less mechanistically resolved.

Show evidence (2 references)

PMID:20942659 SUPPORT Model Organism

"The activities of lipoprotein lipase and endothelial lipase, key enzymes in the metabolism of circulating triglycerides and HDL cholesterol, respectively, are elevated in Angptl3-knockout mice"

Mouse knockout data establish elevated lipase activity as the mechanism for the triglyceride/HDL phenotypes.

PMID:20942659 SUPPORT Human Clinical

"The mechanism by which deficiency of ANGPTL3 lowers LDL cholesterol remains to be determined."

The authors explicitly state that the LPL/EL-inhibition mechanism explains the triglyceride and HDL-cholesterol phenotypes but not the LDL-cholesterol phenotype, hence PROVISIONAL confidence and PARTIAL support for extending this node's mechanism to the LDL branch.

Enhanced Catabolism of Triglyceride-Rich Lipoproteins

Unrestrained lipoprotein lipase and endothelial lipase activity accelerates catabolism of triglyceride-rich lipoproteins and HDL, lowering triglycerides and HDL cholesterol together with LDL cholesterol rather than selectively lowering apoB-containing particles as in the APOB and PCSK9 routes. Carriers of ANGPTL3 loss-of-function variants additionally show decreased VLDL apoB production and increased LDL fractional catabolism, indicating ANGPTL3 also acts directly on hepatic lipoprotein secretion and clearance independent of its role inhibiting circulating lipases.

triglyceride catabolic process GO:0019433 ↑ INCREASED

Downstream

Reduced Circulating ApoB-Containing Lipoprotein Concentration Accelerated catabolism of VLDL and LDL, together with reduced VLDL apoB production, reduces circulating apoB-lipoprotein concentration.

Decreased HDL cholesterol concentration Endothelial lipase activation also accelerates HDL catabolism, distinguishing this route from the LDL-selective APOB and PCSK9 routes. Unlike the LDL/triglyceride traits, this HDL effect segregates as a strictly recessive trait requiring biallelic ANGPTL3 loss.

Protection Against Coronary Artery Disease Lifelong reduction of all three major apoB/lipid fractions by ANGPTL3 deficiency is associated with reduced coronary atherosclerotic burden and lower odds of coronary artery disease.

Show evidence (1 reference)

PMID:20942659 SUPPORT Human Clinical

"carriers of ANGPTL3 nonsense mutations had decreased rates of VLDL apolipoprotein B production and increased fractional catabolic rates for LDL apolipoprotein B"

Physiological kinetic studies in carriers directly support both reduced VLDL production and increased LDL catabolism.

Protection Against Coronary Artery Disease

A shared downstream consequence of the PCSK9 and ANGPTL3 clearance-enhanced routes: lifelong, moderate reduction of circulating LDL cholesterol (and, for ANGPTL3, triglycerides) from birth is associated with substantially reduced coronary heart disease risk, providing the human-genetics validation for PCSK9-inhibitor and ANGPTL3-inhibitor drug development.

Show evidence (1 reference)

PMID:16554528 SUPPORT Human Clinical

"These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors."

States the general principle that lifelong LDL reduction from PCSK9 loss of function substantially reduces coronary events.

Reduced Circulating ApoB-Containing Lipoprotein Concentration

The convergent biochemical phenotype: plasma apoB and LDL cholesterol persistently below the 5th percentile, reached by three mechanistically distinct routes (reduced hepatic/intestinal apoB production, enhanced hepatic LDL-receptor-mediated clearance, or enhanced lipolytic catabolism of triglyceride-rich lipoproteins).

Downstream

Decreased LDL cholesterol concentration Reduced apoB-lipoprotein particle number is measured as decreased LDL cholesterol.

Hypocholesterolemia Reduced apoB-lipoprotein particle number lowers total cholesterol.

Impaired Intestinal Lipid Absorption When severe (homozygous/compound heterozygous FHBL1), reduced intestinal chylomicron secretion impairs dietary fat absorption. This branch does not occur in heterozygous FHBL1 or in the PCSK9/ANGPTL3 clearance-enhanced routes.

Show evidence (1 reference)

PMID:32039990 SUPPORT Other

"Several mutations in the apolipoprotein (apo) B, proprotein convertase subtilisin kexin 9 (PCSK9) and microsomal triglyceride transfer protein genes result in low or absent levels of apoB and LDL cholesterol (LDL-C) in plasma which cause familial hypobetalipoproteinemia (FHBL) and..."

States the shared convergent biochemical phenotype across the causal genes covered in this entry.

Impaired Intestinal Lipid Absorption

In the severe (homozygous or compound heterozygous FHBL1) form, insufficient intestinal chylomicron secretion impairs absorption and transport of dietary lipid, causing steatorrhea and fat-soluble-vitamin malabsorption. This branch is not seen in heterozygous FHBL1 or in the PCSK9/ANGPTL3 clearance-enhanced routes, which do not affect intestinal chylomicron assembly.

enterocyte CL:0000584

intestinal lipid absorption GO:0098856 ↓ DECREASED

Downstream

Fat malabsorption Defective chylomicron export produces impaired dietary fat absorption.

Reduced Fat-Soluble Vitamin Bioavailability Chylomicron failure impairs absorption and transport of vitamins A, D, E, and K.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency."

GeneReviews lists the characteristic gastrointestinal manifestations of biallelic APOB-FHBL.

Reduced Fat-Soluble Vitamin Bioavailability

Impaired absorption and lipoprotein transport reduce the bioavailability of vitamins A, D, E, and K in severe (biallelic) FHBL1, mirroring the vitamin deficiency of abetalipoproteinemia and driving the same downstream retinal, neurologic, and coagulation complications when untreated.

Downstream

Decreased circulating vitamin E concentration Reduced vitamin E absorption and transport lowers circulating vitamin E, the deficiency most closely tied to neurologic complications.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"In the absence of treatment, affected individuals can develop atypical pigmentation of the retina; progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors; and steatohepatitis, fibrosis, and rarely, cirrhosis of the liver."

GeneReviews describes the untreated natural history driven by fat-soluble-vitamin deficiency.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

18

Digestive 4

Hepatic steatosis FREQUENT HP:0001397

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis."

GeneReviews states hepatic steatosis as a characteristic finding in heterozygous FHBL1.

Cirrhosis VERY_RARE HP:0001394

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"about 5%-10% of individuals with heterozygous APOB-FHBL develop relatively more severe nonalcoholic steatohepatitis requiring medical attention and occasionally progressing to cirrhosis, albeit very rarely"

GeneReviews quantifies the minority of heterozygous carriers who progress to clinically significant liver disease.

Steatorrhea VERY_FREQUENT HP:0002570

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency."

GeneReviews names steatorrhea among the most common clinical findings in biallelic APOB-FHBL.

Hepatomegaly HP:0002240

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency."

GeneReviews names hepatomegaly among the most common findings in biallelic APOB-FHBL.

Eye 1

Abnormal retinal pigmentation HP:0007703

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"In the absence of treatment, affected individuals can develop atypical pigmentation of the retina"

GeneReviews describes untreated retinal pigmentation as a natural-history finding.

Metabolism 2

Decreased HDL cholesterol concentration HP:0003233

Show evidence (1 reference)

PMID:20942659 SUPPORT Human Clinical

"compound heterozygotes had a very low level of HDL cholesterol (mean, 18 mg per deciliter"

Quantifies decreased HDL cholesterol specific to biallelic ANGPTL3 carriers.

Elevated circulating hepatic transaminase concentration HP:0002910

Show evidence (2 references)

PMID:33983694 SUPPORT Other

"Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found."

GeneReviews lists elevated liver enzymes among the findings in APOB-FHBL.

PMID:33983694 SUPPORT Other

"Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis."

GeneReviews states mild liver dysfunction (transaminase elevation) as a main manifestation of heterozygous FHBL1.

Nervous System 3

Areflexia HP:0001284

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors"

GeneReviews lists progressive loss of deep tendon reflexes among untreated neurologic findings.

Ataxia HP:0001251

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors"

GeneReviews lists ataxia among untreated neurologic findings in biallelic disease.

Peripheral neuropathy HP:0009830

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors"

GeneReviews describes the component signs of a peripheral neuropathy pattern (areflexia, sensory loss, weakness) without using the term "peripheral neuropathy" itself, hence PARTIAL.

Growth 1

Failure to thrive HP:0001508

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency."

GeneReviews names failure to thrive / growth deficiency among the most common findings.

Other 7

Decreased LDL cholesterol concentration VERY_FREQUENT HP:0003563

Show evidence (1 reference)

PMID:20942659 SUPPORT Human Clinical

"Familial hypobetalipoproteinemia is an inherited disorder of lipid metabolism defined by very low levels (<5th percentile of age- and sex-specific values) of plasma apolipoprotein B and LDL cholesterol."

States the defining biochemical threshold for the disease across its genetic causes.

Hypocholesterolemia HP:0003146

Show evidence (1 reference)

PMID:37471510 SUPPORT Other

"The lipid profile is one of hypocholesterolemia with low plasma low-density lipoprotein (LDL) cholesterol, low plasma high-density lipoprotein (HDL) cholesterol, low plasma triglycerides, and low plasma apolipoprotein (apo) B and apo A-I levels."

GeneReviews describes the total-cholesterol reduction as part of the combined hypolipidemia profile.

Fat malabsorption HP:0002630

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"may present from infancy through to adulthood with a range of clinical symptoms including deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction"

GeneReviews describes gastrointestinal dysfunction and fat-soluble vitamin deficiency broadly rather than naming fat malabsorption specifically, hence PARTIAL; the low-fat dietary management recommendation elsewhere in the chapter is consistent with this but is a treatment recommendation, not a phenotype observation.

Decreased circulating vitamin E concentration HP:0100513

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction"

GeneReviews links fat-soluble vitamin deficiency (including vitamin E) to the neurologic complications of biallelic disease.

Acanthocytosis HP:0001927

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found."

GeneReviews lists acanthocytosis among the findings in biallelic APOB-FHBL.

Hyperbilirubinemia HP:0002904

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found."

GeneReviews lists hyperbilirubinemia among the findings in biallelic APOB-FHBL.

Decreased triglyceride level Hypotriglyceridemia HP:0012153

Show evidence (1 reference)

PMID:37471510 SUPPORT Other

"The lipid profile is one of hypocholesterolemia with low plasma low-density lipoprotein (LDL) cholesterol, low plasma high-density lipoprotein (HDL) cholesterol, low plasma triglycerides, and low plasma apolipoprotein (apo) B and apo A-I levels."

GeneReviews lists low plasma triglycerides as part of the familial combined hypolipidemia lipid profile.

🧬

Genetic Associations

4

APOB truncating variants (Causative biallelic or heterozygous truncating variants)

Gene: APOB hgnc:603 relationship_type: CAUSATIVE variant_origin: GERMLINE

Semidominant to Autosomal Recessive

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"The diagnosis of biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) or heterozygous APOB-FHBL is established in a proband with either biallelic or a heterozygous pathogenic variant(s), respectively, in APOB identified by molecular genetic testing"

GeneReviews states the molecular diagnostic criterion for both allelic states.

Variants (2)

APOB truncating variants (apoB-2 to apoB-89) Pathogenic

Gene: APOB hgnc:603 loss of function variant

Over 60 distinct truncating (nonsense, frameshift, splice-site) variants have been reported, named by the percent length of full-length apoB-100 translated (e.g., apoB-67 is the amino-terminal 67% of apoB-100). Severity of the biochemical and clinical phenotype generally scales with truncation length.

Functional effects

Hepatic and intestinal apoB-lipoprotein assembly and secretion loss-of-function

Truncating variants reduce apoB production and impair VLDL/chylomicron assembly and secretion.

Show evidence (1 reference)

PMID:24751931 SUPPORT Other

"Over 60 mutations producing truncations in the apoB gene ranging from apoB2 to apoB-89 have been identified as causes of FHBL"

Documents the size and nomenclature of the truncating APOB allelic series.

p.(Arg490Trp) (c.1468C>T) missense founder variant Pathogenic

Gene: APOB hgnc:603 missense variant

A rare missense variant (rather than a truncation) in APOB exon 11, also historically numbered p.(Arg463Trp). Identified as a founder allele accounting for approximately 71% of FHBL probands in a Lebanese cohort, with the same mutant haplotype shared across unrelated families, and separately reported in families of Italian, Canadian, Spanish, and Dutch origin.

Show evidence (1 reference)

PMID:34564380 SUPPORT Human Clinical

"we found that 71% of the recruited probands and their affected relatives were heterozygous for the p.(Arg490Trp) variant in the APOB gene"

Reports the founder-allele frequency and segregation with FHBL in the Lebanese cohort.

PNPLA3 hepatic-fibrosis modifier (Modifier of liver-disease severity/progression in APOB-FHBL1, not independently causative of hypobetalipoproteinemia)

Gene: PNPLA3 hgnc:18590 relationship_type: MODIFIER variant_origin: GERMLINE

Show evidence (1 reference)

PMID:41473260 SUPPORT Human Clinical

"PNPLA3 and TM6SF2 have been extensively validated as risk factors for MASLD,89,90 and the TM6SF2 E167K and PNPLA3 I148M variants can promote the profibrotic phenotype of hepatic stellate cells.91,92 Cases have been reported with combined APOB and PNPLA3 variants leading to fibrosis or cirrhosis,93"

Reports PNPLA3 I148M as a validated modifier that can promote fibrosis progression when co-occurring with a causal APOB variant.

PCSK9 loss-of-function variants (Causative heterozygous loss-of-function variants)

Gene: PCSK9 hgnc:20001 relationship_type: CAUSATIVE variant_origin: GERMLINE

Autosomal Dominant

Show evidence (1 reference)

PMID:16554528 SUPPORT Human Clinical

"sequence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) that are associated with reduced plasma levels of LDL cholesterol"

Establishes the PCSK9-LDL cholesterol association at population scale.

Variants (1)

PCSK9 nonsense variants (Y142X, C679X) Pathogenic

Gene: PCSK9 hgnc:20001 loss of function variant

Nonsense mutations identified in African American subjects with low LDL cholesterol, common in that population (combined frequency ~2%) but rare in European Americans.

Functional effects

PCSK9-mediated LDL receptor degradation loss-of-function

Nonsense variants abolish PCSK9 protease activity, preventing LDL receptor degradation.

Show evidence (1 reference)

PMID:15654334 SUPPORT Human Clinical

"we sequenced the coding region of PCSK9 in 128 subjects (50% African American) with low plasma levels of LDL and found two nonsense mutations (Y142X and C679X)"

Identifies the two founding PCSK9 loss-of-function nonsense variants.

ANGPTL3 loss-of-function variants (Causative biallelic loss-of-function variants (codominant for LDL/triglycerides, recessive for HDL))

Gene: ANGPTL3 hgnc:491 relationship_type: CAUSATIVE variant_origin: GERMLINE

Autosomal Recessive

Show evidence (1 reference)

PMID:37471510 SUPPORT Other

"The molecular diagnosis of familial combined hypolipidemia is established in a proband with suggestive laboratory findings and biallelic pathogenic variants in ANGPTL3 identified by molecular genetic testing."

GeneReviews states the molecular diagnostic criterion for the biallelic disease.

Variants (1)

ANGPTL3 nonsense variants (S17X, E129X) Pathogenic

Gene: ANGPTL3 hgnc:491 loss of function variant

Two independent nonsense mutations identified by exome sequencing in siblings with combined hypolipidemia; compound heterozygotes had markedly lower LDL cholesterol, triglycerides, and HDL cholesterol than heterozygous or non-carrier relatives.

Functional effects

Inhibition of lipoprotein lipase and endothelial lipase loss-of-function

Nonsense variants abolish secreted ANGPTL3, removing its inhibitory restraint on both lipases.

Show evidence (1 reference)

PMID:20942659 SUPPORT Human Clinical

"ANGPTL3 harbored two nonsense variants: a single-nucleotide variant... that introduces a nonsense mutation at position 129, resulting in the amino acid mutation E129X; and a double nucleotide variant... that introduces a nonsense mutation at position 17, resulting in the amino acid mutation S17X"

Identifies the two founding ANGPTL3 loss-of-function nonsense variants.

💊

Medical Actions

7

Low-fat diet with fat-soluble vitamin supplementation

Category: Therapeutic Action: dietary intervention Ontology label: Dietary Intervention NCIT:C15447

For biallelic (severe) FHBL1, a low-fat diet (<30% of total calories) with adequate caloric intake plus high-dose oral vitamin A, D, E, and K supplementation, mirroring management of abetalipoproteinemia. No treatment is typically required for heterozygous FHBL1, PCSK9 loss-of-function, or ANGPTL3 deficiency.

Mechanism Target:

MODULATES Impaired Intestinal Lipid Absorption — A low-fat diet reduces the dietary lipid burden on the impaired intestinal chylomicron-export pathway in biallelic FHBL1.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"low-fat diet (<30% of total calories) while ensuring adequate caloric intake; high-dose oral fat-soluble vitamin supplementation (vitamin E: 100-300 IU/kg/day; vitamin A: 100-400 IU/kg/day; vitamin D: 800-1200 IU/day; vitamin K: 5-35 mg/week)"

GeneReviews specifies the dietary and vitamin management regimen for biallelic APOB-FHBL.

MODULATES Reduced Fat-Soluble Vitamin Bioavailability — High-dose oral fat-soluble vitamin supplementation increases vitamin availability despite persistent intestinal malabsorption.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"high-dose oral fat-soluble vitamin supplementation may ameliorate or prevent clinical features of APOB-FHBL"

GeneReviews supports vitamin replacement as ameliorating or preventing clinical features.

Show evidence (2 references)

PMID:33983694 SUPPORT Other

"Individuals with heterozygous APOB-FHBL: no treatment typically required."

GeneReviews states that heterozygous FHBL1 generally requires no treatment, in contrast to the biallelic form.

PMID:33983694 SUPPORT Other

"reduce their vitamin A supplement dose by 50%"

GeneReviews specifies the pregnancy-specific vitamin A dose adjustment for biallelic FHBL1.

Liver transplantation

Category: Therapeutic Action: organ transplantation Ontology label: Organ Transplantation NCIT:C15289

Considered for biallelic (severe) FHBL1 patients who progress to end-stage liver disease from chronic hepatic triglyceride retention and steatohepatitis.

Mechanism Target:

BYPASSES Cirrhosis — Transplantation replaces the failing liver rather than correcting the underlying APOB-lipoprotein secretion defect, which persists in extrahepatic tissue.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"liver transplantation may be considered for those with end-stage liver disease"

GeneReviews lists liver transplantation as a management option for end-stage liver disease in biallelic APOB-FHBL.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"liver transplantation may be considered for those with end-stage liver disease"

GeneReviews lists liver transplantation as a management option for end-stage liver disease in biallelic APOB-FHBL.

Multisystem surveillance for biallelic FHBL1

Category: Monitoring Action: supportive care Ontology label: Supportive Care NCIT:C15747

Longitudinal follow-up in biallelic (severe) FHBL1 assesses growth, gastrointestinal symptoms, lipid profile, liver function, fat-soluble vitamins, coagulation, and other chemistries, alongside periodic ophthalmologic, neurologic, hepatic imaging, and bone-density evaluation, mirroring the surveillance schedule used for abetalipoproteinemia.

Show evidence (2 references)

PMID:33983694 SUPPORT Other

"laboratory studies to include lipid profile, liver function tests, vitamin levels, INR, calcium, phosphorus, uric acid, CBC, vitamin B12, folate and TSH every 1-2 years"

GeneReviews specifies the biochemical surveillance schedule for biallelic APOB-FHBL.

PMID:33983694 SUPPORT Other

"ophthalmology evaluation and neurologic examination every 6-12 months after age 10 years; hepatic ultrasound and bone mineral densitometry studies every 3-5 years after age 10 years"

GeneReviews specifies the periodic specialist and imaging surveillance schedule for biallelic APOB-FHBL.

Hepatic surveillance for heterozygous FHBL1

Category: Monitoring Action: supportive care Ontology label: Supportive Care NCIT:C15747

Periodic liver function testing and hepatic ultrasound because heterozygous FHBL1 carries a real, if usually mild, risk of hepatic steatosis progressing to steatohepatitis, fibrosis, or rarely cirrhosis and hepatocellular carcinoma.

Show evidence (1 reference)

PMID:24751931 SUPPORT Other

"The recent reports of cirrhosis and hepatocellular carcinoma associated with FHBL suggest that liver enzymes should be monitored in subjects with FHBL and if elevated, hepatic imaging be considered"

The review recommends liver-enzyme monitoring and imaging surveillance for FHBL carriers.

Genetic counseling and family evaluation

Category: Counseling / Informational Action: Genetic Counseling NCIT:C15240

Counseling addresses the autosomal recessive recurrence risk for the severe biallelic FHBL1 and ANGPTL3-deficiency forms, carrier testing, and evaluation of at-risk relatives when a familial variant is known.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being heterozygous for APOB-FHBL and having laboratory findings and (rarely) clinical features, and a 25% chance of being unaffected and not a heterozygote."

GeneReviews provides the autosomal-recessive recurrence-risk framework for biallelic APOB-FHBL.

Evolocumab

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: evolocumab NCIT:C174672

Fully human monoclonal antibody against PCSK9. Not a treatment for hypobetalipoproteinemia itself - PCSK9 loss-of-function hypobetalipoproteinemia is clinically benign and requires no treatment - but a pharmacological reproduction of the exact PCSK9-loss-of-function mechanism curated in this entry, developed and used to lower LDL cholesterol in hypercholesterolemic patients (see kb/disorders/Autosomal_Dominant_Hypercholesterolemia_3.yaml). Included here as the therapeutic validation of this entry's human-genetics rationale.

Mechanism Target:

ACTIVATES Reduced PCSK9-Mediated LDL Receptor Degradation — Evolocumab neutralizes circulating PCSK9, pharmacologically reproducing the reduced-LDL-receptor-degradation state that PCSK9 loss-of-function variants produce genetically, increasing hepatic LDL clearance.

Show evidence (1 reference)

PMID:28304224 SUPPORT Human Clinical

"Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%."

States the drug's molecular target and quantitative effect on LDL cholesterol.

Show evidence (1 reference)

PMID:16554528 SUPPORT Human Clinical

"moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events"

This entry's own human-genetics finding is the rationale cited for developing PCSK9-inhibitor therapy.

Evinacumab

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: evinacumab NCIT:C169973

Monoclonal antibody against ANGPTL3. Not a treatment for hypobetalipoproteinemia itself - ANGPTL3 deficiency is clinically silent and requires no treatment - but a pharmacological reproduction of this entry's ANGPTL3-loss-of-function mechanism, developed and approved to lower LDL cholesterol in homozygous familial hypercholesterolemia, where it lowers LDL cholesterol by an LDL-receptor-independent route. Included here as the therapeutic validation of this entry's human-genetics rationale.

Mechanism Target:

ACTIVATES Loss of ANGPTL3-Mediated Lipase Inhibition — Evinacumab neutralizes circulating ANGPTL3, pharmacologically reproducing the loss-of-ANGPTL3-inhibition state that biallelic ANGPTL3 loss-of-function variants produce genetically, de-repressing lipoprotein and endothelial lipase and lowering LDL, HDL, and triglycerides.

Show evidence (1 reference)

PMID:32813947 SUPPORT Human Clinical

"Loss-of-function variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial..."

The pivotal trial's own background statement explicitly frames evinacumab as reproducing the ANGPTL3 loss-of-function state curated in this entry.

Show evidence (1 reference)

PMID:32813947 SUPPORT Human Clinical

"At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group"

Quantifies evinacumab's LDL-lowering effect in a randomized trial, the clinical validation of the mechanism curated in this entry.

🔬

Biochemical Markers

1

LDL cholesterol and apoB (DECREASED)

Context: Plasma

Show evidence (1 reference)

PMID:38710625 SUPPORT Human Clinical

"We searched PubMed for HoFHBL1 cases with genetic diagnosis and found that HoFHBL1 patients had LDL-C ＜15 mg/dL and/or apoB ＜15 mg/dL (typically apoB ＜5 mg/dL), except for two cases with a mild phenotype"

Reports the proposed severe biochemical thresholds for homozygous FHBL1.

🔬

Diagnosis

3

Plasma lipid and apoB measurement

Fasting lipid profile and apoB establish the biochemical phenotype (apoB and LDL cholesterol below the 5th percentile) and should prompt molecular testing. For homozygous/compound heterozygous (severe) FHBL1, a proposed severe threshold of LDL-C and/or apoB below 15 mg/dL (typically apoB below 5 mg/dL) has been used to define eligibility for homozygous-disease-specific management, with rare exceptions of a milder biochemical phenotype.

blood chemistry measurement NCIT:C47868

Results: Absent or extremely low LDL cholesterol and apoB supports severe (biallelic) FHBL1 but does not by itself distinguish it from abetalipoproteinemia; molecular testing and family lipid profiles are required for that distinction.

Show evidence (1 reference)

PMID:38710625 SUPPORT Human Clinical

"We searched PubMed for HoFHBL1 cases with genetic diagnosis and found that HoFHBL1 patients had LDL-C ＜15 mg/dL and/or apoB ＜15 mg/dL (typically apoB ＜5 mg/dL), except for two cases with a mild phenotype"

A 2024 expert review reports the proposed severe biochemical thresholds for homozygous FHBL1 diagnosis, derived from a systematic literature search of genetically confirmed cases.

APOB molecular genetic testing

Identification of a heterozygous (mild/incidental) or biallelic (severe) pathogenic APOB variant confirms APOB-related familial hypobetalipoproteinemia in a patient with the compatible biochemical phenotype.

molecular genetic testing NCIT:C19770

Results: A heterozygous or biallelic pathogenic APOB variant establishes the molecular diagnosis, respectively of heterozygous or biallelic (severe) FHBL1.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"The diagnosis of biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) or heterozygous APOB-FHBL is established in a proband with either biallelic or a heterozygous pathogenic variant(s), respectively, in APOB identified by molecular genetic testing"

GeneReviews states the molecular diagnostic criterion for both allelic states.

Peripheral blood smear morphology

A peripheral blood smear can demonstrate acanthocytosis, a supportive clue in biallelic (severe) FHBL1, as in abetalipoproteinemia, though it cannot by itself distinguish the two.

clinical assessment NCIT:C124351

Results: Acanthocytosis supports a severe hypobetalipoproteinemia diagnosis but is not a substitute for molecular confirmation.

Show evidence (1 reference)

PMID:33983694 SUPPORT Other

"Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found."

GeneReviews lists acanthocytosis among the findings supporting a biallelic APOB-FHBL diagnosis.

📊

Prevalence

5

Black participants, Atherosclerosis Risk in Communities (ARIC) study

Carrier Frequency 2600.0 per 100,000 >1 in 1,000 PCSK9 Loss of Function

2.6% of 3363 Black ARIC participants carried a PCSK9 nonsense mutation (Y142X or C679X), associated with a 28% reduction in mean LDL cholesterol.

Show evidence (1 reference)

PMID:16554528 SUPPORT Human Clinical

"Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol"

Directly reports the PCSK9 loss-of-function carrier frequency in this cohort.

White participants, Atherosclerosis Risk in Communities (ARIC) study

Carrier Frequency 3200.0 per 100,000 >1 in 1,000 PCSK9 Loss of Function

3.2% of 9524 White ARIC participants carried a PCSK9 sequence variant associated with a 15% reduction in LDL cholesterol.

Show evidence (1 reference)

PMID:16554528 SUPPORT Human Clinical

"Of the 9524 white subjects examined, 3.2 percent had a sequence variation in PCSK9 that was associated with a 15 percent reduction in LDL cholesterol"

Directly reports the PCSK9 variant carrier frequency in this cohort.

Campodimele, Italy (founder population)

Carrier Frequency 9400.0 per 100,000 >1 in 1,000 ANGPTL3 Deficiency

A founder ANGPTL3 S17X nonsense allele was identified as a cause of FHBL in 9.4% of the isolated Campodimele, Italy population, an unusually high carrier frequency for a monogenic hypolipidemia allele.

Show evidence (1 reference)

PMID:24751931 SUPPORT Other

"identified ANGPTL3 S17X as a cause of FHBL in 9.4% of the population of Campodimele, Italy."

Reports the founder-population carrier frequency for this ANGPTL3 allele.

Worldwide

Point Prevalence 33.3–100.0 per 100,000 >1 in 1,000 FHBL1 Heterozygous

Framingham-derived epidemiological estimates place heterozygous FHBL1 at about 1:1,000-1:3,000 individuals; large-scale sequencing studies corroborate the more prevalent end, finding APOB protein-truncating variants in about 0.1% (1:1,000) of the general population.

Show evidence (2 references)

PMID:41473260 SUPPORT Other

"Epidemiological data from Framingham, USA, showed that heterozygous FHBL (He-FHBL) cases occur in about 1:1,000–1:3,000 individuals, while homozygous or compound heterozygous FHBL (Ho-FHBL) cases are extremely rare, with a prevalence of less than one in a million."

States the heterozygous FHBL1 population prevalence range from Framingham epidemiological data.

PMID:41473260 SUPPORT Other

"Large-scale sequencing studies indicated that APOB protein-truncating variants causing FHBL occur in about 0.1% of the general population."

Corroborates the more prevalent end of the Framingham range with a modern sequencing-based estimate.

Worldwide

Point Prevalence ≤0.1 per 100,000 <1 in 1,000,000 FHBL1 Homozygous

Homozygous or compound heterozygous (severe) FHBL1 is extremely rare, with an estimated prevalence below 1 per million.

Show evidence (1 reference)

PMID:41473260 SUPPORT Other

"homozygous or compound heterozygous FHBL (Ho-FHBL) cases are extremely rare, with a prevalence of less than one in a million."

States the biallelic (severe) FHBL1 population prevalence.

🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Hypobetalipoproteinemia:

Abetalipoproteinemia MONDO:0008692

Overlapping Features The closest phenotypic mimic of severe (biallelic) FHBL1: MTTP-related abetalipoproteinemia produces a very similar clinical and biochemical picture (fat malabsorption, hepatic steatosis, fat-soluble-vitamin deficiency, acanthocytosis) but arises from a distinct mechanism - impaired apoB-particle *lipidation* by microsomal triglyceride transfer protein acting on structurally normal apoB alleles, rather than a defect in apoB dosage or clearance.

Distinguishing Features

Biallelic pathogenic APOB variants establish severe FHBL1; biallelic pathogenic MTTP variants establish abetalipoproteinemia.
Obligate heterozygous parents of a severe FHBL1 proband have approximately half-normal apoB-containing lipoproteins, whereas obligate heterozygous parents of an abetalipoproteinemia proband usually have normal lipids - the key family-lipid discriminator.

Show evidence (2 references)

PMID:24288038 SUPPORT Other

"mutations either in both alleles of the MTP (alias MTTP) gene encoding microsomal triglyceride transfer protein (MTP) or both alleles of the APOB gene itself in the case of ABL and HHBL, respectively."

The review distinguishes the two phenocopies by their causal genes.

PMID:24288038 SUPPORT Other

"Obligate heterozygote parents of ABL patients usually have normal lipids"

Supplies the family-lipid discriminator between the two mimics.

🐁

Animal Models

1

Apob-38.9 heterozygous mouse (FHBL1 model)

Species

Mouse

Genotype

Apob-38.9 heterozygous (Apobec-1(-/-)/Apob(38.9/+) or Apob(38.9/100)), producing only apoB-38.9 and apoB-100

Publication

PMID:13130124

Pathograph links

Impaired Hepatic and Intestinal ApoB-Lipoprotein Assembly and Secretion recapitulates fidelity: high Apob-38.9 heterozygous mice reproduce the disproportionate (well beyond the 50% gene-dosage expectation) reduction in hepatic apoB-100 secretion documented in human heterozygous FHBL1, and localize the defect in vivo and in primary hepatocytes to a secretion step rather than reduced synthesis from the intact allele.

Readouts

Hepatic apoB-100 secretion rate

Direction: DECREASED

Interpretation: An 80% in vivo reduction in apoB-100 secretion, far exceeding the 50% expected from simple gene dosage, mirrors the disproportionate (70-80%) reduction measured in human heterozygous FHBL1 and localizes the defect to hepatocyte secretion efficiency rather than synthesis.

Show evidence (1 reference)

PMID:13130124 SUPPORT Model Organism

"Rates of secretion were reduced by 80%, rather than the expected 50%, in both Apobec-1(-/-)/Apob(38.9/+) and Apob(38.9/100) mice compared with those of the respective Apobec-1(-/-)/Apob(+/+) and Apob(100/100) control mice."

Directly reports the quantitative, genuinely murine in vivo hepatic apoB-100 secretion-rate readout in this model.

Show evidence (1 reference)

PMID:13130124 SUPPORT Model Organism

"Continuous labeling and pulse-chase experiments in primary hepatocyte cultures revealed that rates of apoB-100 synthesis by Apobec-1(-/-)/Apob(38.9/+) and Apob(38.9/100) hepatocytes were reduced to the expected 50% of those of the respective controls, but the efficiency of secretion of apoB-100..."

Localizes the mouse-model defect specifically to hepatocyte secretion efficiency rather than synthesis, supporting use of this model for the secretion node.

Show evidence (1 reference)

PMID:13130124 SUPPORT Human Clinical

"Lipoprotein kinetics studies have shown that production rates of apoB-100 are reduced by 70-80% in heterozygous FHBL humans, instead of the expected 50%."

The paper's own background statement establishes the human phenotype (70-80% reduction, not 50%) that motivated developing this mouse model - cited here as HUMAN_CLINICAL, distinct from the model's own MODEL_ORGANISM readout above.

{ }

Source YAML

click to show

name: Hypobetalipoproteinemia
creation_date: "2026-08-26T16:00:00Z"
category: Mendelian
description: >
  Hypobetalipoproteinemia is a genetically heterogeneous group of inherited
  lipoprotein-metabolism disorders defined by plasma apolipoprotein B (apoB)
  and LDL cholesterol persistently below the 5th percentile. Three
  mechanistically distinct monogenic routes converge on this shared
  biochemical phenotype: APOB truncating variants that limit hepatic and
  intestinal apoB-lipoprotein production (familial hypobetalipoproteinemia 1,
  FHBL1), PCSK9 loss-of-function variants that enhance hepatic LDL-receptor
  recycling and clearance, and ANGPTL3 loss-of-function variants that
  de-repress lipoprotein and endothelial lipase activity, lowering LDL, HDL,
  and triglycerides together (familial hypobetalipoproteinemia 2 / familial
  combined hypolipidemia). Heterozygous FHBL1 is usually asymptomatic or
  associated only with mild hepatic steatosis; homozygous or compound
  heterozygous FHBL1 recapitulates severe fat malabsorption, hepatic
  steatosis, and fat-soluble-vitamin deficiency. PCSK9 and ANGPTL3
  loss-of-function are generally clinically benign and, unlike FHBL1, are not
  associated with hepatic steatosis; both are protective against coronary
  artery disease and are the human-genetics rationale for PCSK9-inhibitor and
  ANGPTL3-inhibitor lipid-lowering biologics.
disease_term:
  preferred_term: hypobetalipoproteinemia
  term:
    id: MONDO:0017774
    label: hypobetalipoproteinemia
synonyms:
- FHBL
- Familial hypobetalipoproteinemia
notes: >-
  This entry models the apoB-dosage/clearance axis of hypobetalipoproteinemia
  and is deliberately distinct from kb/disorders/Abetalipoproteinemia.yaml
  (MTTP, MONDO:0008692), which MONDO also nests as a child of MONDO:0017774
  alongside chylomicron retention disease (SAR1B). Abetalipoproteinemia is a
  recessive defect of apoB-particle *lipidation* by microsomal triglyceride
  transfer protein, acting on structurally normal apoB alleles; this entry
  covers codominant/dominant apoB-*dosage* and apoB-*clearance* defects
  acting directly on APOB, PCSK9, or ANGPTL3. The two are close phenotypic
  mimics in their most severe (biallelic APOB) forms - obligate heterozygous
  parents of an abetalipoproteinemia proband usually have normal lipids,
  while obligate heterozygous parents of a severe FHBL1 proband have
  approximately half-normal apoB-containing lipoproteins, the discriminating
  family-lipid clue between the two. kb/disorders/Familial_Defective_Apolipoprotein_B-100.yaml
  covers the opposite (hyper-) axis of APOB variation: missense substitutions
  in the LDL-receptor-binding region that impair apoB-100 ligand function and
  *raise* LDL cholesterol, the mirror image of the truncating,
  production-limiting APOB alleles curated here.
parents:
- Hypolipoproteinemia
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
    evidence:
    - reference: PMID:24751931
      reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Several mutations in the apoB, MTP and PCSK9 genes result in low or absent levels of apoB and LDL-C in plasma and cause familial hypobetalipoproteinemia (FHBL) and abetalipoproteinemia (ABL)."
      explanation: Characterizes hypobetalipoproteinemia as a disorder of lipid/lipoprotein metabolism.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:20942659
      reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Familial hypobetalipoproteinemia is an inherited disorder of lipid metabolism defined by very low levels (<5th percentile of age- and sex-specific values) of plasma apolipoprotein B and LDL cholesterol. Familial hypobetalipoproteinemia is genetically heterogeneous."
      explanation: Establishes hypobetalipoproteinemia as a Mendelian, genetically heterogeneous disorder.
has_subtypes:
- name: FHBL1 Heterozygous
  display_name: Heterozygous Familial Hypobetalipoproteinemia 1 (APOB)
  subtype_term:
    preferred_term: familial hypobetalipoproteinemia 1
    term:
      id: MONDO:0014252
      label: familial hypobetalipoproteinemia 1
  description: >-
    Heterozygous carriage of one APOB truncating (nonsense, frameshift, or
    canonical splice-site) allele. Usually identified incidentally through
    low LDL cholesterol on routine lipid panels and is frequently
    asymptomatic biochemically, though hepatic steatosis and mild
    transaminase elevation are the main clinical manifestations because the
    truncated apoB variant is co-produced with the normal allele's product
    and can accumulate in hepatocytes even as less apoB-lipoprotein reaches
    plasma.
  genes:
  - preferred_term: APOB
    term:
      id: hgnc:603
      label: APOB
  inheritance:
  - name: Semidominant (Codominant)
    inheritance_term:
      preferred_term: Semidominant inheritance
      term:
        id: HP:0032113
        label: Semidominant inheritance
    evidence:
    - reference: PMID:24751931
      reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "FHBL is an autosomal codominant disorder characterized by apoB < 5th percentile and LDL-C usually between 20–50 mg/dL"
      explanation: States the codominant (semidominant) mode of inheritance for the FHBL1 biochemical trait.
- name: FHBL1 Homozygous
  display_name: Homozygous or Compound Heterozygous Familial Hypobetalipoproteinemia 1 (APOB)
  subtype_term:
    preferred_term: familial hypobetalipoproteinemia 1
    term:
      id: MONDO:0014252
      label: familial hypobetalipoproteinemia 1
  description: >-
    Two APOB truncating alleles (homozygous or compound heterozygous),
    producing a severe phenotype that closely mimics abetalipoproteinemia:
    very low or absent apoB-containing lipoproteins, gastrointestinal and
    neurologic dysfunction, fat-soluble-vitamin deficiency, hepatomegaly, and
    steatorrhea. GeneReviews classifies the biallelic-caused disease itself
    as autosomal recessive, distinct from the codominant biochemical trait
    seen in single-allele carriers.
  genes:
  - preferred_term: APOB
    term:
      id: hgnc:603
      label: APOB
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:33983694
      reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "APOB-related familial hypobetalipoproteinemia (APOB-FHBL) caused by homozygous (or compound heterozygous) pathogenic variants in APOB is inherited in an autosomal recessive manner."
      explanation: GeneReviews states the autosomal recessive pattern for the biallelic (severe) disease.
- name: PCSK9 Loss of Function
  display_name: PCSK9 Loss-of-Function Hypobetalipoproteinemia
  description: >-
    Heterozygous PCSK9 nonsense or loss-of-function missense variants reduce
    or abolish PCSK9-mediated degradation of the hepatic LDL receptor,
    increasing receptor recycling and hepatic LDL clearance. Unlike FHBL1,
    this is a clearance-enhancement rather than a production-limiting
    mechanism, is not associated with hepatic steatosis or fat
    malabsorption, and is clinically benign and cardioprotective; it is the
    human-genetics basis for PCSK9-inhibitor therapy.
  genes:
  - preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  inheritance:
  - name: Autosomal Dominant (Gene-Dosage)
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    evidence:
    - reference: PMID:16554528
      reference_title: "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol"
      explanation: A single heterozygous PCSK9 nonsense allele is sufficient to measurably lower LDL cholesterol, consistent with dominant/gene-dosage transmission.
- name: ANGPTL3 Deficiency
  display_name: ANGPTL3-Related Familial Combined Hypolipidemia (FHBL2)
  subtype_term:
    preferred_term: familial hypobetalipoproteinemia 2
    term:
      id: MONDO:0011505
      label: familial hypobetalipoproteinemia 2
  description: >-
    Biallelic ANGPTL3 loss-of-function variants abolish ANGPTL3-mediated
    inhibition of lipoprotein lipase and endothelial lipase, increasing
    catabolism of triglyceride-rich lipoproteins. Because ANGPTL3 normally
    restrains clearance of VLDL, LDL, and HDL alike, its complete loss
    produces a combined hypolipidemia affecting all three lipoprotein
    classes rather than a selective LDL/apoB defect, distinguishing it from
    FHBL1 and PCSK9 loss of function. GeneReviews reports the syndrome as
    clinically silent - "not associated with any pathologic signs or
    symptoms" - and, like PCSK9 loss of function, it is not associated with
    hepatic steatosis. It is the mechanistic basis for ANGPTL3-inhibitor
    (evinacumab) therapy.
  genes:
  - preferred_term: ANGPTL3
    term:
      id: hgnc:491
      label: ANGPTL3
  inheritance:
  - name: Autosomal Recessive (Codominant for LDL/Triglycerides)
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:37471510
      reference_title: "Familial Combined Hypolipidemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Familial combined hypolipidemia is inherited in an autosomal recessive manner."
      explanation: GeneReviews states the autosomal recessive pattern for the full clinical/biallelic syndrome.
    - reference: PMID:20942659
      reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Family members who were heterozygous for either mutation had plasma levels of LDL cholesterol and triglycerides that were intermediate between the levels in persons with neither mutation and those with both mutations, findings consistent with a codominant mode of inheritance for the LDL cholesterol and triglyceride phenotypes."
      explanation: >-
        Shows the LDL-cholesterol and triglyceride traits are codominant
        (gene-dosage dependent) even though the full combined-hypolipidemia
        syndrome is formally classified as autosomal recessive.
    - reference: PMID:20942659
      reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In contrast, the level of HDL cholesterol appears to segregate as a recessive trait."
      explanation: >-
        Documents that the HDL-cholesterol reduction specifically follows a
        strictly recessive pattern, unlike the codominant LDL/triglyceride
        traits - a within-family dissociation of inheritance mode by trait.
prevalence:
- population: Black participants, Atherosclerosis Risk in Communities (ARIC) study
  subtype: PCSK9 Loss of Function
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 2600.0
  notes: >-
    2.6% of 3363 Black ARIC participants carried a PCSK9 nonsense mutation
    (Y142X or C679X), associated with a 28% reduction in mean LDL
    cholesterol.
  evidence:
  - reference: PMID:16554528
    reference_title: "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol"
    explanation: Directly reports the PCSK9 loss-of-function carrier frequency in this cohort.
- population: White participants, Atherosclerosis Risk in Communities (ARIC) study
  subtype: PCSK9 Loss of Function
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 3200.0
  notes: >-
    3.2% of 9524 White ARIC participants carried a PCSK9 sequence variant
    associated with a 15% reduction in LDL cholesterol.
  evidence:
  - reference: PMID:16554528
    reference_title: "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 9524 white subjects examined, 3.2 percent had a sequence variation in PCSK9 that was associated with a 15 percent reduction in LDL cholesterol"
    explanation: Directly reports the PCSK9 variant carrier frequency in this cohort.
- population: Campodimele, Italy (founder population)
  subtype: ANGPTL3 Deficiency
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 9400.0
  notes: >-
    A founder ANGPTL3 S17X nonsense allele was identified as a cause of FHBL
    in 9.4% of the isolated Campodimele, Italy population, an unusually high
    carrier frequency for a monogenic hypolipidemia allele.
  evidence:
  - reference: PMID:24751931
    reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "identified ANGPTL3 S17X as a cause of FHBL in 9.4% of the population of Campodimele, Italy."
    explanation: Reports the founder-population carrier frequency for this ANGPTL3 allele.
- population: Worldwide
  subtype: FHBL1 Heterozygous
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 33.3
  rate_high: 100.0
  notes: >-
    Framingham-derived epidemiological estimates place heterozygous FHBL1
    at about 1:1,000-1:3,000 individuals; large-scale sequencing studies
    corroborate the more prevalent end, finding APOB protein-truncating
    variants in about 0.1% (1:1,000) of the general population.
  evidence:
  - reference: PMID:41473260
    reference_title: "Current and Emerging Issues in Familial Hypobetalipoproteinemia-related Steatotic Liver Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Epidemiological data from Framingham, USA, showed that heterozygous FHBL (He-FHBL) cases occur in about 1:1,000–1:3,000 individuals, while homozygous or compound heterozygous FHBL (Ho-FHBL) cases are extremely rare, with a prevalence of less than one in a million."
    explanation: States the heterozygous FHBL1 population prevalence range from Framingham epidemiological data.
  - reference: PMID:41473260
    reference_title: "Current and Emerging Issues in Familial Hypobetalipoproteinemia-related Steatotic Liver Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Large-scale sequencing studies indicated that APOB protein-truncating variants causing FHBL occur in about 0.1% of the general population."
    explanation: Corroborates the more prevalent end of the Framingham range with a modern sequencing-based estimate.
- population: Worldwide
  subtype: FHBL1 Homozygous
  measure_type: POINT_PREVALENCE
  prevalence_class: BELOW_1_IN_1000000
  rate_high: 0.1
  notes: >-
    Homozygous or compound heterozygous (severe) FHBL1 is extremely rare,
    with an estimated prevalence below 1 per million.
  evidence:
  - reference: PMID:41473260
    reference_title: "Current and Emerging Issues in Familial Hypobetalipoproteinemia-related Steatotic Liver Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "homozygous or compound heterozygous FHBL (Ho-FHBL) cases are extremely rare, with a prevalence of less than one in a million."
    explanation: States the biallelic (severe) FHBL1 population prevalence.
pathophysiology:
- name: APOB Truncating Variant
  description: >-
    A nonsense, frameshift, or canonical splice-site variant in APOB
    truncates the apoB open reading frame, producing a shortened apoB
    protein (apoB-XX nomenclature, denoting the percentage of full-length
    apoB translated) instead of full-length apoB-100/apoB-48. Over 60
    distinct truncating APOB mutations, ranging from apoB-2 to apoB-89, have
    been reported as causes of FHBL1.
  role: trigger
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  genes:
  - preferred_term: APOB
    term:
      id: hgnc:603
      label: APOB
  genetic_context:
    gene:
      preferred_term: APOB
      term:
        id: hgnc:603
        label: APOB
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      A truncating allele produces less protein and/or a protein that
      assembles and secretes lipoprotein particles less efficiently than
      full-length apoB - a straightforward loss-of-function call, in
      contrast to the partial, conformational loss-of-function of the
      ligand-binding-region missense alleles curated in
      Familial_Defective_Apolipoprotein_B-100.yaml.
  evidence:
  - reference: PMID:24751931
    reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Over 60 mutations producing truncations in the apoB gene ranging from apoB2 to apoB-89 have been identified as causes of FHBL"
    explanation: Documents the range of truncating APOB alleles causing FHBL1.
  downstream:
  - target: Impaired Hepatic and Intestinal ApoB-Lipoprotein Assembly and Secretion
    description: Truncated apoB is produced in reduced quantity and is secreted far less efficiently than the predicted 50% gene-dosage share.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24751931
      reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Although there is one normal allele in heterozygous FHBL, plasma apoB-100 levels are approximately 24% of normal rather than the predicted 50%"
      explanation: Stable-isotope kinetic data show heterozygous truncating alleles disproportionately reduce apoB output below the simple gene-dosage expectation.
- name: Impaired Hepatic and Intestinal ApoB-Lipoprotein Assembly and Secretion
  description: >-
    Truncated apoB reduces the pool of apoB-lipoprotein particles available
    for hepatic VLDL and intestinal chylomicron assembly and secretion, a
    production-limited mechanism distinct from the lipidation defect of
    abetalipoproteinemia. Kinetic studies attribute the disproportionately
    low heterozygous apoB levels to markedly reduced VLDL apoB-100 secretion,
    decreased LDL apoB-100 production, increased VLDL catabolism, and
    extremely low secretion of the truncated species itself.
  role: mediator
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: enterocyte
    term:
      id: CL:0000584
      label: enterocyte
  biological_processes:
  - preferred_term: very-low-density lipoprotein particle assembly
    term:
      id: GO:0034379
      label: very-low-density lipoprotein particle assembly
    modifier: DECREASED
  evidence:
  - reference: PMID:24751931
    reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "these lower than expected levels result from a 74% lower secretion rate of VLDL apoB-100 from the liver, decreased production of LDL apoB-100, increased catabolism of VLDL and extremely low secretion of the truncated apoB"
    explanation: Kinetic evidence directly establishes the reduced hepatic secretion mechanism.
  downstream:
  - target: Reduced Circulating ApoB-Containing Lipoprotein Concentration
    description: Fewer apoB-lipoprotein particles are secreted into plasma.
    causal_link_type: DIRECT
  - target: Hepatic Triglyceride Retention
    description: >-
      Reduced hepatic apoB secretion decreases triglyceride export from the
      liver in VLDL, producing hepatic steatosis even as less apoB-lipoprotein
      reaches plasma.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24751931
      reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This decreased secretion of apoB from the liver results in decreased triglyceride export from the liver, which in turn leads to the development of fatty liver"
      explanation: States the direct causal step from reduced apoB secretion to hepatic triglyceride retention and fatty liver.
- name: Hepatic Triglyceride Retention
  description: >-
    Reduced hepatic VLDL export retains triglyceride within hepatocytes,
    producing hepatic steatosis that can progress to steatohepatitis,
    fibrosis, and rarely cirrhosis or hepatocellular carcinoma, even in
    heterozygous carriers. This hepatic-storage consequence is
    characteristic of the APOB production-limited route and is not seen with
    the PCSK9 or ANGPTL3 clearance-enhanced routes.
  role: mediator
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: lipid storage
    term:
      id: GO:0019915
      label: lipid storage
    modifier: INCREASED
  evidence:
  - reference: PMID:24751931
    reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 32 subjects with FHBL, average hepatic fat content measured by MR spectroscopy was 14.8% + 12.0% compared to 5.2% + 5.9%, respectively, for 33 normolipidemic controls"
    explanation: Directly measures increased hepatic fat content in FHBL subjects compared to matched controls.
  downstream:
  - target: Hepatic steatosis
    description: Hepatocyte triglyceride retention is observed as hepatic steatosis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33983694
      reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis."
      explanation: GeneReviews states hepatic steatosis as the characteristic manifestation of heterozygous FHBL1.
  - target: Cirrhosis
    description: >-
      Chronic hepatic triglyceride accumulation can progress to
      steatohepatitis and, rarely, cirrhosis or hepatocellular carcinoma,
      even in individuals with only a heterozygous truncating allele.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic hepatocyte lipid accumulation and steatohepatitis
    evidence:
    - reference: PMID:24751931
      reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Steatohepatitis, cirrhosis and hepatocellular carcinoma have all been described in subjects with truncated apoBs"
      explanation: Documents progression to cirrhosis and hepatocellular carcinoma in truncated-apoB carriers.
- name: PCSK9 Loss-of-Function Variant
  description: >-
    A PCSK9 nonsense or loss-of-function missense variant reduces or
    abolishes secreted PCSK9 activity. First identified through sequencing
    of PCSK9 in subjects with low plasma LDL specifically to test whether
    loss-of-function variants would have the mirror-image effect of the
    gain-of-function PCSK9 variants that cause autosomal dominant
    hypercholesterolemia (kb/disorders/Autosomal_Dominant_Hypercholesterolemia_3.yaml).
  role: trigger
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  genes:
  - preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  genetic_context:
    gene:
      preferred_term: PCSK9
      term:
        id: hgnc:20001
        label: PCSK9
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      The mirror-image lesion class to the gain-of-function PCSK9 missense
      variants that cause autosomal dominant hypercholesterolemia type 3
      (ADH3): here, nonsense or loss-of-function missense variants reduce or
      abolish PCSK9 protease activity rather than enhancing it.
  evidence:
  - reference: PMID:15654334
    reference_title: "Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To test whether loss-of-function mutations in PCSK9 have the opposite effect, we sequenced the coding region of PCSK9 in 128 subjects (50% African American) with low plasma levels of LDL and found two nonsense mutations (Y142X and C679X)"
    explanation: The discovery study explicitly frames these as loss-of-function variants, the mirror image of the known gain-of-function hypercholesterolemia alleles.
  downstream:
  - target: Reduced PCSK9-Mediated LDL Receptor Degradation
    description: Loss of PCSK9 function removes the normal restraint on hepatic LDL receptor turnover.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24751931
      reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Loss of function mutations in the PCSK9 gene prevent the PCSK9-mediated degradation of the LDL receptor and thus increase uptake of LDL by the liver"
      explanation: States the direct causal mechanism linking PCSK9 loss of function to reduced LDL receptor degradation.
- name: Reduced PCSK9-Mediated LDL Receptor Degradation
  description: >-
    PCSK9 normally binds the hepatic LDL receptor and directs it toward
    lysosomal degradation after endocytosis rather than recycling it to the
    cell surface. Loss-of-function PCSK9 variants remove this restraint, so
    more LDL receptor recycles back to the hepatocyte surface. This is the
    exact mechanistic node that PCSK9-inhibitor biologics (evolocumab,
    alirocumab) pharmacologically reproduce to lower LDL cholesterol in
    hypercholesterolemia.
  role: mediator
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: low-density lipoprotein particle receptor catabolic process
    term:
      id: GO:0032802
      label: low-density lipoprotein particle receptor catabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:24751931
    reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PCSK9 is a secreted serine protease that enhances the degradation of the LDL-receptor. Loss of function mutations in the PCSK9 gene prevent the PCSK9-mediated degradation of the LDL receptor and thus increase uptake of LDL by the liver, a process leading to a 30 to 70% reduction in plasma LDL-C levels"
    explanation: States both the normal PCSK9 mechanism and the quantitative effect of its loss on plasma LDL cholesterol.
  downstream:
  - target: Increased Hepatic LDL Receptor Density
    description: Reduced receptor degradation increases steady-state hepatic LDL receptor abundance available for uptake.
    causal_link_type: DIRECT
- name: Increased Hepatic LDL Receptor Density
  description: >-
    More LDL receptor is available at the hepatocyte surface for
    receptor-mediated uptake of circulating LDL, increasing hepatic
    clearance of apoB-containing lipoproteins from plasma.
  role: mediator
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Reduced Circulating ApoB-Containing Lipoprotein Concentration
    description: Enhanced hepatic LDL-receptor-mediated uptake increases clearance of circulating LDL, unlike the production-limited APOB route.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16554528
      reference_title: "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "these mutations were associated with a 28 percent reduction in mean LDL cholesterol and an 88 percent reduction in the risk of CHD"
      explanation: Population data directly link PCSK9 loss-of-function variants to reduced LDL cholesterol.
- name: ANGPTL3 Loss-of-Function Variant
  description: >-
    Biallelic ANGPTL3 loss-of-function variants (compound heterozygous or
    homozygous nonsense/frameshift alleles) abolish secreted ANGPTL3
    activity. Discovered by whole-exome sequencing of two siblings with
    combined hypolipidemia not linked to APOB.
  role: trigger
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  genes:
  - preferred_term: ANGPTL3
    term:
      id: hgnc:491
      label: ANGPTL3
  genetic_context:
    gene:
      preferred_term: ANGPTL3
      term:
        id: hgnc:491
        label: ANGPTL3
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Nonsense and frameshift alleles that abolish secreted ANGPTL3 protein;
      the LDL-cholesterol and triglyceride phenotypes are gene-dosage
      dependent (codominant) while the HDL-cholesterol phenotype requires
      biallelic loss (recessive), a within-locus dissociation of inheritance
      mode by trait.
  evidence:
  - reference: PMID:20942659
    reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These two participants were compound heterozygotes for two distinct nonsense mutations in ANGPTL3 (encoding the angiopoietin-like 3 protein)."
    explanation: The discovery study identifies the causal ANGPTL3 nonsense mutations by exome sequencing.
  downstream:
  - target: Loss of ANGPTL3-Mediated Lipase Inhibition
    description: Loss of ANGPTL3 removes its normal inhibitory restraint on lipoprotein lipase and endothelial lipase.
    causal_link_type: DIRECT
- name: Loss of ANGPTL3-Mediated Lipase Inhibition
  description: >-
    ANGPTL3 normally inhibits lipoprotein lipase and endothelial lipase, the
    key enzymes that hydrolyze circulating triglyceride-rich lipoproteins
    and HDL, respectively. Loss of ANGPTL3 function increases the activity
    of both enzymes. This is the established mechanism for the triglyceride
    and HDL-cholesterol reductions; the mechanism by which ANGPTL3
    deficiency also lowers LDL cholesterol is less well resolved (see
    mechanism_confidence below).
  role: mediator
  biological_scale: MOLECULAR
  mechanism_confidence: PROVISIONAL
  molecular_functions:
  - preferred_term: lipoprotein lipase activity
    term:
      id: GO:0004465
      label: lipoprotein lipase activity
    modifier: INCREASED
  evidence:
  - reference: PMID:20942659
    reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The activities of lipoprotein lipase and endothelial lipase, key enzymes in the metabolism of circulating triglycerides and HDL cholesterol, respectively, are elevated in Angptl3-knockout mice"
    explanation: Mouse knockout data establish elevated lipase activity as the mechanism for the triglyceride/HDL phenotypes.
  - reference: PMID:20942659
    reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mechanism by which deficiency of ANGPTL3 lowers LDL cholesterol remains to be determined."
    explanation: >-
      The authors explicitly state that the LPL/EL-inhibition mechanism
      explains the triglyceride and HDL-cholesterol phenotypes but not the
      LDL-cholesterol phenotype, hence PROVISIONAL confidence and PARTIAL
      support for extending this node's mechanism to the LDL branch.
  downstream:
  - target: Enhanced Catabolism of Triglyceride-Rich Lipoproteins
    description: Increased lipase activity accelerates lipolytic catabolism of VLDL and HDL; the LDL branch is less mechanistically resolved.
    causal_link_type: DIRECT
- name: Enhanced Catabolism of Triglyceride-Rich Lipoproteins
  description: >-
    Unrestrained lipoprotein lipase and endothelial lipase activity
    accelerates catabolism of triglyceride-rich lipoproteins and HDL,
    lowering triglycerides and HDL cholesterol together with LDL cholesterol
    rather than selectively lowering apoB-containing particles as in the
    APOB and PCSK9 routes. Carriers of ANGPTL3 loss-of-function variants
    additionally show decreased VLDL apoB production and increased LDL
    fractional catabolism, indicating ANGPTL3 also acts directly on hepatic
    lipoprotein secretion and clearance independent of its role inhibiting
    circulating lipases.
  role: mediator
  biological_scale: TISSUE
  mechanism_confidence: ESTABLISHED
  biological_processes:
  - preferred_term: triglyceride catabolic process
    term:
      id: GO:0019433
      label: triglyceride catabolic process
    modifier: INCREASED
  evidence:
  - reference: PMID:20942659
    reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "carriers of ANGPTL3 nonsense mutations had decreased rates of VLDL apolipoprotein B production and increased fractional catabolic rates for LDL apolipoprotein B"
    explanation: Physiological kinetic studies in carriers directly support both reduced VLDL production and increased LDL catabolism.
  downstream:
  - target: Reduced Circulating ApoB-Containing Lipoprotein Concentration
    description: Accelerated catabolism of VLDL and LDL, together with reduced VLDL apoB production, reduces circulating apoB-lipoprotein concentration.
    causal_link_type: DIRECT
  - target: Decreased HDL cholesterol concentration
    description: >-
      Endothelial lipase activation also accelerates HDL catabolism,
      distinguishing this route from the LDL-selective APOB and PCSK9
      routes. Unlike the LDL/triglyceride traits, this HDL effect segregates
      as a strictly recessive trait requiring biallelic ANGPTL3 loss.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20942659
      reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "compound heterozygotes had a very low level of HDL cholesterol (mean, 18 mg per deciliter"
      explanation: Quantifies the HDL-cholesterol reduction specific to biallelic (compound heterozygous) carriers.
  - target: Protection Against Coronary Artery Disease
    description: >-
      Lifelong reduction of all three major apoB/lipid fractions by ANGPTL3
      deficiency is associated with reduced coronary atherosclerotic burden
      and lower odds of coronary artery disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - sustained reduction of circulating LDL cholesterol and triglycerides
    evidence:
    - reference: PMID:28385496
      reference_title: "ANGPTL3 Deficiency and Protection Against Coronary Artery Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The 3 individuals with complete ANGPTL3 deficiency showed no evidence of coronary atherosclerotic plaque."
      explanation: Direct imaging evidence of absent coronary atherosclerosis in complete ANGPTL3 deficiency.
    - reference: PMID:28385496
      reference_title: "ANGPTL3 Deficiency and Protection Against Coronary Artery Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Carrier status was associated with a 34% reduction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04)."
      explanation: Population-level genetic association between heterozygous ANGPTL3 loss-of-function carrier status and reduced CAD odds.
- name: Protection Against Coronary Artery Disease
  description: >-
    A shared downstream consequence of the PCSK9 and ANGPTL3
    clearance-enhanced routes: lifelong, moderate reduction of circulating
    LDL cholesterol (and, for ANGPTL3, triglycerides) from birth is
    associated with substantially reduced coronary heart disease risk,
    providing the human-genetics validation for PCSK9-inhibitor and
    ANGPTL3-inhibitor drug development.
  role: outcome
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:16554528
    reference_title: "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors."
    explanation: States the general principle that lifelong LDL reduction from PCSK9 loss of function substantially reduces coronary events.
- name: Reduced Circulating ApoB-Containing Lipoprotein Concentration
  description: >-
    The convergent biochemical phenotype: plasma apoB and LDL cholesterol
    persistently below the 5th percentile, reached by three mechanistically
    distinct routes (reduced hepatic/intestinal apoB production, enhanced
    hepatic LDL-receptor-mediated clearance, or enhanced lipolytic
    catabolism of triglyceride-rich lipoproteins).
  role: central_effector
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:32039990
    reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Several mutations in the apolipoprotein (apo) B, proprotein convertase subtilisin kexin 9 (PCSK9) and microsomal triglyceride transfer protein genes result in low or absent levels of apoB and LDL cholesterol (LDL-C) in plasma which cause familial hypobetalipoproteinemia (FHBL) and abetalipoproteinemia (ABL)."
    explanation: States the shared convergent biochemical phenotype across the causal genes covered in this entry.
  downstream:
  - target: Decreased LDL cholesterol concentration
    description: Reduced apoB-lipoprotein particle number is measured as decreased LDL cholesterol.
    causal_link_type: DIRECT
  - target: Hypocholesterolemia
    description: Reduced apoB-lipoprotein particle number lowers total cholesterol.
    causal_link_type: DIRECT
  - target: Impaired Intestinal Lipid Absorption
    description: >-
      When severe (homozygous/compound heterozygous FHBL1), reduced
      intestinal chylomicron secretion impairs dietary fat absorption. This
      branch does not occur in heterozygous FHBL1 or in the PCSK9/ANGPTL3
      clearance-enhanced routes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - failure of intestinal chylomicron export in severe FHBL1
    evidence:
    - reference: PMID:20942659
      reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Persons with hypobetalipoproteinemia may also have fat malabsorption due to impaired incorporation of dietary fats into chylomicrons in the absorptive cells of the intestine."
      explanation: States the intestinal fat-malabsorption branch specific to the apoB production-limited route.
- name: Impaired Intestinal Lipid Absorption
  description: >-
    In the severe (homozygous or compound heterozygous FHBL1) form,
    insufficient intestinal chylomicron secretion impairs absorption and
    transport of dietary lipid, causing steatorrhea and fat-soluble-vitamin
    malabsorption. This branch is not seen in heterozygous FHBL1 or in the
    PCSK9/ANGPTL3 clearance-enhanced routes, which do not affect intestinal
    chylomicron assembly.
  role: mediator
  biological_scale: CELLULAR
  mechanism_confidence: ESTABLISHED
  cell_types:
  - preferred_term: enterocyte
    term:
      id: CL:0000584
      label: enterocyte
  biological_processes:
  - preferred_term: intestinal lipid absorption
    term:
      id: GO:0098856
      label: intestinal lipid absorption
    modifier: DECREASED
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency."
    explanation: GeneReviews lists the characteristic gastrointestinal manifestations of biallelic APOB-FHBL.
  downstream:
  - target: Fat malabsorption
    description: Defective chylomicron export produces impaired dietary fat absorption.
    causal_link_type: DIRECT
  - target: Reduced Fat-Soluble Vitamin Bioavailability
    description: Chylomicron failure impairs absorption and transport of vitamins A, D, E, and K.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired intestinal uptake and transport of fat-soluble vitamins
    evidence:
    - reference: PMID:33983694
      reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Individuals with biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) may present from infancy through to adulthood with a range of clinical symptoms including deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction."
      explanation: GeneReviews links intestinal dysfunction to fat-soluble-vitamin deficiency and downstream neurologic disease.
- name: Reduced Fat-Soluble Vitamin Bioavailability
  description: >-
    Impaired absorption and lipoprotein transport reduce the bioavailability
    of vitamins A, D, E, and K in severe (biallelic) FHBL1, mirroring the
    vitamin deficiency of abetalipoproteinemia and driving the same
    downstream retinal, neurologic, and coagulation complications when
    untreated.
  role: mediator
  biological_scale: ORGANISM
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the absence of treatment, affected individuals can develop atypical pigmentation of the retina; progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors; and steatohepatitis, fibrosis, and rarely, cirrhosis of the liver."
    explanation: GeneReviews describes the untreated natural history driven by fat-soluble-vitamin deficiency.
  downstream:
  - target: Decreased circulating vitamin E concentration
    description: Reduced vitamin E absorption and transport lowers circulating vitamin E, the deficiency most closely tied to neurologic complications.
    causal_link_type: DIRECT
phenotypes:
- name: Decreased LDL cholesterol concentration
  category: Biochemical
  frequency: VERY_FREQUENT
  description: The defining biochemical phenotype across all subtypes, apoB and LDL cholesterol below the 5th percentile.
  phenotype_term:
    preferred_term: Decreased LDL cholesterol concentration
    term:
      id: HP:0003563
      label: Decreased LDL cholesterol concentration
  evidence:
  - reference: PMID:20942659
    reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Familial hypobetalipoproteinemia is an inherited disorder of lipid metabolism defined by very low levels (<5th percentile of age- and sex-specific values) of plasma apolipoprotein B and LDL cholesterol."
    explanation: States the defining biochemical threshold for the disease across its genetic causes.
- name: Hypocholesterolemia
  category: Biochemical
  description: Total cholesterol is reduced secondary to the reduced apoB-lipoprotein pool.
  phenotype_term:
    preferred_term: Hypocholesterolemia
    term:
      id: HP:0003146
      label: Hypocholesterolemia
  evidence:
  - reference: PMID:37471510
    reference_title: "Familial Combined Hypolipidemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The lipid profile is one of hypocholesterolemia with low plasma low-density lipoprotein (LDL) cholesterol, low plasma high-density lipoprotein (HDL) cholesterol, low plasma triglycerides, and low plasma apolipoprotein (apo) B and apo A-I levels."
    explanation: GeneReviews describes the total-cholesterol reduction as part of the combined hypolipidemia profile.
- name: Decreased HDL cholesterol concentration
  category: Biochemical
  subtype: ANGPTL3 Deficiency
  description: >-
    Characteristic of biallelic ANGPTL3 deficiency, distinguishing combined
    hypolipidemia from the LDL-selective APOB and PCSK9 routes; segregates
    as a recessive trait requiring biallelic loss.
  phenotype_term:
    preferred_term: Decreased HDL cholesterol concentration
    term:
      id: HP:0003233
      label: Decreased HDL cholesterol concentration
  evidence:
  - reference: PMID:20942659
    reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "compound heterozygotes had a very low level of HDL cholesterol (mean, 18 mg per deciliter"
    explanation: Quantifies decreased HDL cholesterol specific to biallelic ANGPTL3 carriers.
- name: Hepatic steatosis
  category: Hepatic
  subtype: FHBL1 Heterozygous
  frequency: FREQUENT
  description: The main clinical manifestation of heterozygous FHBL1, due to defective hepatic triglyceride export.
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis."
    explanation: GeneReviews states hepatic steatosis as a characteristic finding in heterozygous FHBL1.
- name: Cirrhosis
  category: Hepatic
  subtype: FHBL1 Heterozygous
  frequency: VERY_RARE
  description: >-
    Rare but reported progression from hepatic steatosis to steatohepatitis
    and cirrhosis, occasionally with hepatocellular carcinoma, even in
    individuals with only one truncating APOB allele.
  phenotype_term:
    preferred_term: Cirrhosis
    term:
      id: HP:0001394
      label: Cirrhosis
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "about 5%-10% of individuals with heterozygous APOB-FHBL develop relatively more severe nonalcoholic steatohepatitis requiring medical attention and occasionally progressing to cirrhosis, albeit very rarely"
    explanation: GeneReviews quantifies the minority of heterozygous carriers who progress to clinically significant liver disease.
- name: Fat malabsorption
  category: Gastrointestinal
  subtype: FHBL1 Homozygous
  description: >-
    Intestinal lipid absorption is impaired in severe (homozygous/compound
    heterozygous) FHBL1. Frequency is deliberately omitted: GeneReviews
    documents the clinical sign (steatorrhea, curated separately below) and
    the underlying gastrointestinal dysfunction, but does not quantify "fat
    malabsorption" as a distinct, separately banded finding.
  phenotype_term:
    preferred_term: Fat malabsorption
    term:
      id: HP:0002630
      label: Fat malabsorption
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "may present from infancy through to adulthood with a range of clinical symptoms including deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction"
    explanation: >-
      GeneReviews describes gastrointestinal dysfunction and fat-soluble
      vitamin deficiency broadly rather than naming fat malabsorption
      specifically, hence PARTIAL; the low-fat dietary management
      recommendation elsewhere in the chapter is consistent with this but
      is a treatment recommendation, not a phenotype observation.
- name: Steatorrhea
  category: Gastrointestinal
  subtype: FHBL1 Homozygous
  frequency: VERY_FREQUENT
  description: Fatty, malodorous stools from fat malabsorption; one of the most common clinical findings in biallelic APOB-FHBL.
  phenotype_term:
    preferred_term: Steatorrhea
    term:
      id: HP:0002570
      label: Steatorrhea
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency."
    explanation: GeneReviews names steatorrhea among the most common clinical findings in biallelic APOB-FHBL.
- name: Hepatomegaly
  category: Hepatic
  subtype: FHBL1 Homozygous
  description: A common clinical finding in biallelic APOB-FHBL, alongside steatorrhea and failure to thrive.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency."
    explanation: GeneReviews names hepatomegaly among the most common findings in biallelic APOB-FHBL.
- name: Failure to thrive
  category: Growth
  subtype: FHBL1 Homozygous
  description: Growth deficiency is among the most common findings in biallelic APOB-FHBL.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency."
    explanation: GeneReviews names failure to thrive / growth deficiency among the most common findings.
- name: Decreased circulating vitamin E concentration
  category: Biochemical
  subtype: FHBL1 Homozygous
  description: Fat-soluble vitamin deficiency in severe (biallelic) FHBL1, the deficiency most closely tied to neurologic complications.
  phenotype_term:
    preferred_term: Decreased circulating vitamin E concentration
    term:
      id: HP:0100513
      label: Decreased circulating vitamin E concentration
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction"
    explanation: GeneReviews links fat-soluble vitamin deficiency (including vitamin E) to the neurologic complications of biallelic disease.
- name: Acanthocytosis
  category: Hematologic
  subtype: FHBL1 Homozygous
  description: Acanthocytosis and hyperbilirubinemia may accompany biallelic APOB-FHBL, as in abetalipoproteinemia.
  phenotype_term:
    preferred_term: Acanthocytosis
    term:
      id: HP:0001927
      label: Acanthocytosis
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found."
    explanation: GeneReviews lists acanthocytosis among the findings in biallelic APOB-FHBL.
- name: Elevated circulating hepatic transaminase concentration
  category: Hepatic
  subtype: FHBL1 Heterozygous
  description: >-
    Mild transaminase elevation is a main manifestation of heterozygous
    FHBL1, and can also occur in biallelic (severe) disease.
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found."
    explanation: GeneReviews lists elevated liver enzymes among the findings in APOB-FHBL.
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis."
    explanation: GeneReviews states mild liver dysfunction (transaminase elevation) as a main manifestation of heterozygous FHBL1.
- name: Hyperbilirubinemia
  category: Hematologic
  subtype: FHBL1 Homozygous
  description: Hyperbilirubinemia may accompany biallelic APOB-FHBL, as in abetalipoproteinemia.
  phenotype_term:
    preferred_term: Hyperbilirubinemia
    term:
      id: HP:0002904
      label: Hyperbilirubinemia
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found."
    explanation: GeneReviews lists hyperbilirubinemia among the findings in biallelic APOB-FHBL.
- name: Abnormal retinal pigmentation
  category: Ophthalmologic
  subtype: FHBL1 Homozygous
  description: Untreated biallelic disease can develop atypical retinal pigmentation from chronic fat-soluble-vitamin deficiency.
  phenotype_term:
    preferred_term: Abnormal retinal pigmentation
    term:
      id: HP:0007703
      label: Abnormal retinal pigmentation
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the absence of treatment, affected individuals can develop atypical pigmentation of the retina"
    explanation: GeneReviews describes untreated retinal pigmentation as a natural-history finding.
- name: Areflexia
  category: Neurologic
  subtype: FHBL1 Homozygous
  description: Progressive loss of deep tendon reflexes can occur in untreated biallelic disease, mirroring abetalipoproteinemia.
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors"
    explanation: GeneReviews lists progressive loss of deep tendon reflexes among untreated neurologic findings.
- name: Ataxia
  category: Neurologic
  subtype: FHBL1 Homozygous
  description: Ataxia can occur as part of untreated neurologic involvement in biallelic disease.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors"
    explanation: GeneReviews lists ataxia among untreated neurologic findings in biallelic disease.
- name: Peripheral neuropathy
  category: Neurologic
  subtype: FHBL1 Homozygous
  description: >-
    Untreated biallelic disease can develop a peripheral neuropathy pattern
    (loss of deep tendon reflexes, vibratory sense, and proprioception; muscle
    pain or weakness), mirroring the vitamin-E-associated neuromuscular
    injury of abetalipoproteinemia.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors"
    explanation: >-
      GeneReviews describes the component signs of a peripheral neuropathy
      pattern (areflexia, sensory loss, weakness) without using the term
      "peripheral neuropathy" itself, hence PARTIAL.
- name: Decreased triglyceride level
  category: Biochemical
  subtype: ANGPTL3 Deficiency
  description: Triglycerides are markedly reduced together with LDL and HDL cholesterol in ANGPTL3 deficiency.
  phenotype_term:
    preferred_term: Hypotriglyceridemia
    term:
      id: HP:0012153
      label: Hypotriglyceridemia
  evidence:
  - reference: PMID:37471510
    reference_title: "Familial Combined Hypolipidemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The lipid profile is one of hypocholesterolemia with low plasma low-density lipoprotein (LDL) cholesterol, low plasma high-density lipoprotein (HDL) cholesterol, low plasma triglycerides, and low plasma apolipoprotein (apo) B and apo A-I levels."
    explanation: GeneReviews lists low plasma triglycerides as part of the familial combined hypolipidemia lipid profile.
biochemical:
- name: LDL cholesterol and apoB
  context: Plasma
  presence: DECREASED
  notes: >-
    Below the 5th percentile for age and sex across all subtypes. In
    biallelic (severe) FHBL1, a proposed severe threshold of LDL-C and/or
    apoB below 15 mg/dL (typically apoB below 5 mg/dL) has been used to
    define homozygous-disease eligibility, with rare exceptions of a milder
    biochemical phenotype; excessively truncated apoB species may be
    undetectable in plasma altogether.
  evidence:
  - reference: PMID:38710625
    reference_title: "Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We searched PubMed for HoFHBL1 cases with genetic diagnosis and found that HoFHBL1 patients had LDL-C ＜15 mg/dL and/or apoB ＜15 mg/dL (typically apoB ＜5 mg/dL), except for two cases with a mild phenotype"
    explanation: Reports the proposed severe biochemical thresholds for homozygous FHBL1.
genetic:
- name: APOB truncating variants
  gene_term:
    preferred_term: APOB
    term:
      id: hgnc:603
      label: APOB
  association: Causative biallelic or heterozygous truncating variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  inheritance:
  - name: Semidominant to Autosomal Recessive
    inheritance_term:
      preferred_term: Semidominant inheritance
      term:
        id: HP:0032113
        label: Semidominant inheritance
  variants:
  - name: APOB truncating variants (apoB-2 to apoB-89)
    description: >
      Over 60 distinct truncating (nonsense, frameshift, splice-site)
      variants have been reported, named by the percent length of
      full-length apoB-100 translated (e.g., apoB-67 is the amino-terminal
      67% of apoB-100). Severity of the biochemical and clinical phenotype
      generally scales with truncation length.
    gene:
      preferred_term: APOB
      term:
        id: hgnc:603
        label: APOB
    clinical_significance: PATHOGENIC
    type: loss_of_function_variant
    functional_effects:
    - function: Hepatic and intestinal apoB-lipoprotein assembly and secretion
      description: Truncating variants reduce apoB production and impair VLDL/chylomicron assembly and secretion.
      type: loss-of-function
    evidence:
    - reference: PMID:24751931
      reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Over 60 mutations producing truncations in the apoB gene ranging from apoB2 to apoB-89 have been identified as causes of FHBL"
      explanation: Documents the size and nomenclature of the truncating APOB allelic series.
  - name: p.(Arg490Trp) (c.1468C>T) missense founder variant
    description: >
      A rare missense variant (rather than a truncation) in APOB exon 11,
      also historically numbered p.(Arg463Trp). Identified as a founder
      allele accounting for approximately 71% of FHBL probands in a
      Lebanese cohort, with the same mutant haplotype shared across
      unrelated families, and separately reported in families of Italian,
      Canadian, Spanish, and Dutch origin.
    gene:
      preferred_term: APOB
      term:
        id: hgnc:603
        label: APOB
    clinical_significance: PATHOGENIC
    type: missense_variant
    evidence:
    - reference: PMID:34564380
      reference_title: "Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "we found that 71% of the recruited probands and their affected relatives were heterozygous for the p.(Arg490Trp) variant in the APOB gene"
      explanation: Reports the founder-allele frequency and segregation with FHBL in the Lebanese cohort.
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) or heterozygous APOB-FHBL is established in a proband with either biallelic or a heterozygous pathogenic variant(s), respectively, in APOB identified by molecular genetic testing"
    explanation: GeneReviews states the molecular diagnostic criterion for both allelic states.
- name: PNPLA3 hepatic-fibrosis modifier
  gene_term:
    preferred_term: PNPLA3
    term:
      id: hgnc:18590
      label: PNPLA3
  association: Modifier of liver-disease severity/progression in APOB-FHBL1, not independently causative of hypobetalipoproteinemia
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  notes: >-
    PNPLA3 I148M is a common MASLD risk variant, independent of the APOB
    truncating/missense alleles that cause FHBL1 itself. Co-occurrence of a
    PNPLA3 risk variant with a causal APOB variant has been reported to
    promote progression to fibrosis or cirrhosis, offering a candidate
    explanation for the variable hepatic severity among carriers of the
    same APOB allele. Curated as a liver-disease modifier, not as a second
    causal gene for the hypobetalipoproteinemia biochemical phenotype.
  evidence:
  - reference: PMID:41473260
    reference_title: "Current and Emerging Issues in Familial Hypobetalipoproteinemia-related Steatotic Liver Diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PNPLA3 and TM6SF2 have been extensively validated as risk factors for MASLD,89,90 and the TM6SF2 E167K and PNPLA3 I148M variants can promote the profibrotic phenotype of hepatic stellate cells.91,92 Cases have been reported with combined APOB and PNPLA3 variants leading to fibrosis or cirrhosis,93"
    explanation: Reports PNPLA3 I148M as a validated modifier that can promote fibrosis progression when co-occurring with a causal APOB variant.
- name: PCSK9 loss-of-function variants
  gene_term:
    preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  association: Causative heterozygous loss-of-function variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  inheritance:
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  variants:
  - name: PCSK9 nonsense variants (Y142X, C679X)
    description: >
      Nonsense mutations identified in African American subjects with low
      LDL cholesterol, common in that population (combined frequency ~2%)
      but rare in European Americans.
    gene:
      preferred_term: PCSK9
      term:
        id: hgnc:20001
        label: PCSK9
    clinical_significance: PATHOGENIC
    type: loss_of_function_variant
    functional_effects:
    - function: PCSK9-mediated LDL receptor degradation
      description: Nonsense variants abolish PCSK9 protease activity, preventing LDL receptor degradation.
      type: loss-of-function
    evidence:
    - reference: PMID:15654334
      reference_title: "Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "we sequenced the coding region of PCSK9 in 128 subjects (50% African American) with low plasma levels of LDL and found two nonsense mutations (Y142X and C679X)"
      explanation: Identifies the two founding PCSK9 loss-of-function nonsense variants.
  evidence:
  - reference: PMID:16554528
    reference_title: "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sequence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) that are associated with reduced plasma levels of LDL cholesterol"
    explanation: Establishes the PCSK9-LDL cholesterol association at population scale.
- name: ANGPTL3 loss-of-function variants
  gene_term:
    preferred_term: ANGPTL3
    term:
      id: hgnc:491
      label: ANGPTL3
  association: Causative biallelic loss-of-function variants (codominant for LDL/triglycerides, recessive for HDL)
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  variants:
  - name: ANGPTL3 nonsense variants (S17X, E129X)
    description: >
      Two independent nonsense mutations identified by exome sequencing in
      siblings with combined hypolipidemia; compound heterozygotes had
      markedly lower LDL cholesterol, triglycerides, and HDL cholesterol
      than heterozygous or non-carrier relatives.
    gene:
      preferred_term: ANGPTL3
      term:
        id: hgnc:491
        label: ANGPTL3
    clinical_significance: PATHOGENIC
    type: loss_of_function_variant
    functional_effects:
    - function: Inhibition of lipoprotein lipase and endothelial lipase
      description: Nonsense variants abolish secreted ANGPTL3, removing its inhibitory restraint on both lipases.
      type: loss-of-function
    evidence:
    - reference: PMID:20942659
      reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "ANGPTL3 harbored two nonsense variants: a single-nucleotide variant... that introduces a nonsense mutation at position 129, resulting in the amino acid mutation E129X; and a double nucleotide variant... that introduces a nonsense mutation at position 17, resulting in the amino acid mutation S17X"
      explanation: Identifies the two founding ANGPTL3 loss-of-function nonsense variants.
  evidence:
  - reference: PMID:37471510
    reference_title: "Familial Combined Hypolipidemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The molecular diagnosis of familial combined hypolipidemia is established in a proband with suggestive laboratory findings and biallelic pathogenic variants in ANGPTL3 identified by molecular genetic testing."
    explanation: GeneReviews states the molecular diagnostic criterion for the biallelic disease.
animal_models:
- name: Apob-38.9 heterozygous mouse (FHBL1 model)
  species: Mouse
  genotype: >-
    Apob-38.9 heterozygous (Apobec-1(-/-)/Apob(38.9/+) or Apob(38.9/100)),
    producing only apoB-38.9 and apoB-100
  publication: PMID:13130124
  modeled_mechanisms:
  - target: Impaired Hepatic and Intestinal ApoB-Lipoprotein Assembly and Secretion
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Apob-38.9 heterozygous mice reproduce the disproportionate (well
      beyond the 50% gene-dosage expectation) reduction in hepatic apoB-100
      secretion documented in human heterozygous FHBL1, and localize the
      defect in vivo and in primary hepatocytes to a secretion step rather
      than reduced synthesis from the intact allele.
    readouts:
    - name: Hepatic apoB-100 secretion rate
      target: Impaired Hepatic and Intestinal ApoB-Lipoprotein Assembly and Secretion
      direction: DECREASED
      interpretation: >-
        An 80% in vivo reduction in apoB-100 secretion, far exceeding the
        50% expected from simple gene dosage, mirrors the disproportionate
        (70-80%) reduction measured in human heterozygous FHBL1 and
        localizes the defect to hepatocyte secretion efficiency rather than
        synthesis.
      evidence:
      - reference: PMID:13130124
        reference_title: "Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Rates of secretion were reduced by 80%, rather than the expected 50%, in both Apobec-1(-/-)/Apob(38.9/+) and Apob(38.9/100) mice compared with those of the respective Apobec-1(-/-)/Apob(+/+) and Apob(100/100) control mice."
        explanation: Directly reports the quantitative, genuinely murine in vivo hepatic apoB-100 secretion-rate readout in this model.
    evidence:
    - reference: PMID:13130124
      reference_title: "Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Continuous labeling and pulse-chase experiments in primary hepatocyte cultures revealed that rates of apoB-100 synthesis by Apobec-1(-/-)/Apob(38.9/+) and Apob(38.9/100) hepatocytes were reduced to the expected 50% of those of the respective controls, but the efficiency of secretion of apoB-100 was significantly lower in apoB-38.9 heterozygous hepatocytes."
      explanation: Localizes the mouse-model defect specifically to hepatocyte secretion efficiency rather than synthesis, supporting use of this model for the secretion node.
  evidence:
  - reference: PMID:13130124
    reference_title: "Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lipoprotein kinetics studies have shown that production rates of apoB-100 are reduced by 70-80% in heterozygous FHBL humans, instead of the expected 50%."
    explanation: >-
      The paper's own background statement establishes the human phenotype
      (70-80% reduction, not 50%) that motivated developing this mouse
      model - cited here as HUMAN_CLINICAL, distinct from the model's own
      MODEL_ORGANISM readout above.
treatments:
- name: Low-fat diet with fat-soluble vitamin supplementation
  description: >-
    For biallelic (severe) FHBL1, a low-fat diet (<30% of total calories)
    with adequate caloric intake plus high-dose oral vitamin A, D, E, and K
    supplementation, mirroring management of abetalipoproteinemia. No
    treatment is typically required for heterozygous FHBL1, PCSK9
    loss-of-function, or ANGPTL3 deficiency.
  action_category: THERAPEUTIC
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  target_mechanisms:
  - target: Impaired Intestinal Lipid Absorption
    treatment_effect: MODULATES
    description: A low-fat diet reduces the dietary lipid burden on the impaired intestinal chylomicron-export pathway in biallelic FHBL1.
    evidence:
    - reference: PMID:33983694
      reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "low-fat diet (<30% of total calories) while ensuring adequate caloric intake; high-dose oral fat-soluble vitamin supplementation (vitamin E: 100-300 IU/kg/day; vitamin A: 100-400 IU/kg/day; vitamin D: 800-1200 IU/day; vitamin K: 5-35 mg/week)"
      explanation: GeneReviews specifies the dietary and vitamin management regimen for biallelic APOB-FHBL.
  - target: Reduced Fat-Soluble Vitamin Bioavailability
    treatment_effect: MODULATES
    description: High-dose oral fat-soluble vitamin supplementation increases vitamin availability despite persistent intestinal malabsorption.
    evidence:
    - reference: PMID:33983694
      reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "high-dose oral fat-soluble vitamin supplementation may ameliorate or prevent clinical features of APOB-FHBL"
      explanation: GeneReviews supports vitamin replacement as ameliorating or preventing clinical features.
  notes: >-
    Vitamin A dosing needs pregnancy-specific adjustment: women who are
    pregnant or planning to become pregnant should reduce their vitamin A
    supplement dose by 50%, with close monitoring of serum vitamin A
    throughout pregnancy, because vitamin A excess can be harmful to the
    developing fetus while vitamin A itself remains essential and should
    not be discontinued.
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Individuals with heterozygous APOB-FHBL: no treatment typically required."
    explanation: GeneReviews states that heterozygous FHBL1 generally requires no treatment, in contrast to the biallelic form.
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "reduce their vitamin A supplement dose by 50%"
    explanation: GeneReviews specifies the pregnancy-specific vitamin A dose adjustment for biallelic FHBL1.
- name: Liver transplantation
  description: >-
    Considered for biallelic (severe) FHBL1 patients who progress to
    end-stage liver disease from chronic hepatic triglyceride retention and
    steatohepatitis.
  action_category: THERAPEUTIC
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  target_mechanisms:
  - target: Cirrhosis
    treatment_effect: BYPASSES
    description: >-
      Transplantation replaces the failing liver rather than correcting the
      underlying APOB-lipoprotein secretion defect, which persists in
      extrahepatic tissue.
    evidence:
    - reference: PMID:33983694
      reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "liver transplantation may be considered for those with end-stage liver disease"
      explanation: GeneReviews lists liver transplantation as a management option for end-stage liver disease in biallelic APOB-FHBL.
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "liver transplantation may be considered for those with end-stage liver disease"
    explanation: GeneReviews lists liver transplantation as a management option for end-stage liver disease in biallelic APOB-FHBL.
- name: Multisystem surveillance for biallelic FHBL1
  description: >-
    Longitudinal follow-up in biallelic (severe) FHBL1 assesses growth,
    gastrointestinal symptoms, lipid profile, liver function, fat-soluble
    vitamins, coagulation, and other chemistries, alongside periodic
    ophthalmologic, neurologic, hepatic imaging, and bone-density
    evaluation, mirroring the surveillance schedule used for
    abetalipoproteinemia.
  action_category: MONITORING
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "laboratory studies to include lipid profile, liver function tests, vitamin levels, INR, calcium, phosphorus, uric acid, CBC, vitamin B12, folate and TSH every 1-2 years"
    explanation: GeneReviews specifies the biochemical surveillance schedule for biallelic APOB-FHBL.
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ophthalmology evaluation and neurologic examination every 6-12 months after age 10 years; hepatic ultrasound and bone mineral densitometry studies every 3-5 years after age 10 years"
    explanation: GeneReviews specifies the periodic specialist and imaging surveillance schedule for biallelic APOB-FHBL.
- name: Hepatic surveillance for heterozygous FHBL1
  description: >-
    Periodic liver function testing and hepatic ultrasound because
    heterozygous FHBL1 carries a real, if usually mild, risk of hepatic
    steatosis progressing to steatohepatitis, fibrosis, or rarely cirrhosis
    and hepatocellular carcinoma.
  action_category: MONITORING
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:24751931
    reference_title: "Hypobetalipoproteinemia and abetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The recent reports of cirrhosis and hepatocellular carcinoma associated with FHBL suggest that liver enzymes should be monitored in subjects with FHBL and if elevated, hepatic imaging be considered"
    explanation: The review recommends liver-enzyme monitoring and imaging surveillance for FHBL carriers.
- name: Genetic counseling and family evaluation
  description: >-
    Counseling addresses the autosomal recessive recurrence risk for the
    severe biallelic FHBL1 and ANGPTL3-deficiency forms, carrier testing,
    and evaluation of at-risk relatives when a familial variant is known.
  action_category: COUNSELING_INFORMATIONAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being heterozygous for APOB-FHBL and having laboratory findings and (rarely) clinical features, and a 25% chance of being unaffected and not a heterozygote."
    explanation: GeneReviews provides the autosomal-recessive recurrence-risk framework for biallelic APOB-FHBL.
- name: Evolocumab
  description: >-
    Fully human monoclonal antibody against PCSK9. Not a treatment for
    hypobetalipoproteinemia itself - PCSK9 loss-of-function hypobetalipoproteinemia
    is clinically benign and requires no treatment - but a pharmacological
    reproduction of the exact PCSK9-loss-of-function mechanism curated in
    this entry, developed and used to lower LDL cholesterol in
    hypercholesterolemic patients (see
    kb/disorders/Autosomal_Dominant_Hypercholesterolemia_3.yaml). Included
    here as the therapeutic validation of this entry's human-genetics
    rationale.
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: evolocumab
      term:
        id: NCIT:C174672
        label: Evolocumab
  target_mechanisms:
  - target: Reduced PCSK9-Mediated LDL Receptor Degradation
    treatment_effect: ACTIVATES
    description: >-
      Evolocumab neutralizes circulating PCSK9, pharmacologically
      reproducing the reduced-LDL-receptor-degradation state that PCSK9
      loss-of-function variants produce genetically, increasing hepatic LDL
      clearance.
    evidence:
    - reference: PMID:28304224
      reference_title: "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%."
      explanation: States the drug's molecular target and quantitative effect on LDL cholesterol.
  evidence:
  - reference: PMID:16554528
    reference_title: "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events"
    explanation: This entry's own human-genetics finding is the rationale cited for developing PCSK9-inhibitor therapy.
- name: Evinacumab
  description: >-
    Monoclonal antibody against ANGPTL3. Not a treatment for
    hypobetalipoproteinemia itself - ANGPTL3 deficiency is clinically silent
    and requires no treatment - but a pharmacological reproduction of this
    entry's ANGPTL3-loss-of-function mechanism, developed and approved to
    lower LDL cholesterol in homozygous familial hypercholesterolemia, where
    it lowers LDL cholesterol by an LDL-receptor-independent route.
    Included here as the therapeutic validation of this entry's
    human-genetics rationale.
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: evinacumab
      term:
        id: NCIT:C169973
        label: Evinacumab
  target_mechanisms:
  - target: Loss of ANGPTL3-Mediated Lipase Inhibition
    treatment_effect: ACTIVATES
    description: >-
      Evinacumab neutralizes circulating ANGPTL3, pharmacologically
      reproducing the loss-of-ANGPTL3-inhibition state that biallelic
      ANGPTL3 loss-of-function variants produce genetically, de-repressing
      lipoprotein and endothelial lipase and lowering LDL, HDL, and
      triglycerides.
    evidence:
    - reference: PMID:32813947
      reference_title: "Evinacumab for Homozygous Familial Hypercholesterolemia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Loss-of-function variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia."
      explanation: The pivotal trial's own background statement explicitly frames evinacumab as reproducing the ANGPTL3 loss-of-function state curated in this entry.
  evidence:
  - reference: PMID:32813947
    reference_title: "Evinacumab for Homozygous Familial Hypercholesterolemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group"
    explanation: Quantifies evinacumab's LDL-lowering effect in a randomized trial, the clinical validation of the mechanism curated in this entry.
diagnosis:
- name: Plasma lipid and apoB measurement
  diagnosis_term:
    preferred_term: blood chemistry measurement
    term:
      id: NCIT:C47868
      label: Blood Chemistry Measurement
  description: >-
    Fasting lipid profile and apoB establish the biochemical phenotype
    (apoB and LDL cholesterol below the 5th percentile) and should prompt
    molecular testing. For homozygous/compound heterozygous (severe) FHBL1,
    a proposed severe threshold of LDL-C and/or apoB below 15 mg/dL
    (typically apoB below 5 mg/dL) has been used to define eligibility for
    homozygous-disease-specific management, with rare exceptions of a
    milder biochemical phenotype.
  results: >-
    Absent or extremely low LDL cholesterol and apoB supports severe
    (biallelic) FHBL1 but does not by itself distinguish it from
    abetalipoproteinemia; molecular testing and family lipid profiles are
    required for that distinction.
  evidence:
  - reference: PMID:38710625
    reference_title: "Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We searched PubMed for HoFHBL1 cases with genetic diagnosis and found that HoFHBL1 patients had LDL-C ＜15 mg/dL and/or apoB ＜15 mg/dL (typically apoB ＜5 mg/dL), except for two cases with a mild phenotype"
    explanation: A 2024 expert review reports the proposed severe biochemical thresholds for homozygous FHBL1 diagnosis, derived from a systematic literature search of genetically confirmed cases.
- name: APOB molecular genetic testing
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
    qualifiers:
    - predicate:
        preferred_term: has participant
        term:
          id: RO:0000057
          label: has participant
      value:
        preferred_term: APOB
        term:
          id: hgnc:603
          label: APOB
  description: >-
    Identification of a heterozygous (mild/incidental) or biallelic
    (severe) pathogenic APOB variant confirms APOB-related familial
    hypobetalipoproteinemia in a patient with the compatible biochemical
    phenotype.
  results: A heterozygous or biallelic pathogenic APOB variant establishes the molecular diagnosis, respectively of heterozygous or biallelic (severe) FHBL1.
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) or heterozygous APOB-FHBL is established in a proband with either biallelic or a heterozygous pathogenic variant(s), respectively, in APOB identified by molecular genetic testing"
    explanation: GeneReviews states the molecular diagnostic criterion for both allelic states.
- name: Peripheral blood smear morphology
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  description: >-
    A peripheral blood smear can demonstrate acanthocytosis, a supportive
    clue in biallelic (severe) FHBL1, as in abetalipoproteinemia, though it
    cannot by itself distinguish the two.
  results: Acanthocytosis supports a severe hypobetalipoproteinemia diagnosis but is not a substitute for molecular confirmation.
  evidence:
  - reference: PMID:33983694
    reference_title: "APOB-Related Familial Hypobetalipoproteinemia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found."
    explanation: GeneReviews lists acanthocytosis among the findings supporting a biallelic APOB-FHBL diagnosis.
differential_diagnoses:
- name: Abetalipoproteinemia
  description: >-
    The closest phenotypic mimic of severe (biallelic) FHBL1: MTTP-related
    abetalipoproteinemia produces a very similar clinical and biochemical
    picture (fat malabsorption, hepatic steatosis, fat-soluble-vitamin
    deficiency, acanthocytosis) but arises from a distinct mechanism -
    impaired apoB-particle *lipidation* by microsomal triglyceride transfer
    protein acting on structurally normal apoB alleles, rather than a defect
    in apoB dosage or clearance.
  disease_term:
    preferred_term: abetalipoproteinemia
    term:
      id: MONDO:0008692
      label: abetalipoproteinemia
  distinguishing_features:
  - Biallelic pathogenic APOB variants establish severe FHBL1; biallelic pathogenic MTTP variants establish abetalipoproteinemia.
  - Obligate heterozygous parents of a severe FHBL1 proband have approximately half-normal apoB-containing lipoproteins, whereas obligate heterozygous parents of an abetalipoproteinemia proband usually have normal lipids - the key family-lipid discriminator.
  evidence:
  - reference: PMID:24288038
    reference_title: "Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "mutations either in both alleles of the MTP (alias MTTP) gene encoding microsomal triglyceride transfer protein (MTP) or both alleles of the APOB gene itself in the case of ABL and HHBL, respectively."
    explanation: The review distinguishes the two phenocopies by their causal genes.
  - reference: PMID:24288038
    reference_title: "Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Obligate heterozygote parents of ABL patients usually have normal lipids"
    explanation: Supplies the family-lipid discriminator between the two mimics.
discussions:
- discussion_id: gap_fhbl_non_apob_locus
  prompt: >-
    Beyond APOB, PCSK9, and ANGPTL3, what is the causal gene for the
    hypobetalipoproteinemia families linked to a chromosome 3p21
    susceptibility locus, and for the additional families linked to neither
    APOB nor 3p21?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Reduced Circulating ApoB-Containing Lipoprotein Concentration
  rationale: >-
    This entry curates three molecularly resolved causal genes, but the
    literature independently documents at least one additional linked locus
    (chromosome 3p21) and further families with hypobetalipoproteinemia
    linked to neither APOB nor that locus, whose causal gene(s) remain
    unidentified. Unlike heterozygous APOB-FHBL1, the chromosome 3p21-linked
    form does not have increased liver fat, so it is not simply a phenocopy
    of the production-limited APOB route and may represent a fourth distinct
    mechanism.
  evidence:
  - reference: PMID:15818469
    reference_title: "Familial hypobetalipoproteinemia: genetics and metabolism."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Three genetic forms exist: (i) premature stop codon specifying mutations of APOB; (ii) FHBL linked to a susceptibility locus on the chromosome 3p21; and (iii) FHBL linked neither to APOB nor to the chromosome 3p21."
    explanation: States that molecularly uncharacterized non-APOB FHBL loci exist independent of the genes curated in this entry.
  - reference: PMID:15818469
    reference_title: "Familial hypobetalipoproteinemia: genetics and metabolism."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Liver fat in the chromosome 3p21-linked FHBL is normal."
    explanation: Shows the 3p21-linked form does not share the hepatic steatosis mechanism curated for the APOB route, arguing it is mechanistically distinct rather than a minor variant.
  - reference: PMID:20942659
    reference_title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Significant lod scores were not found for regions on chromosomes 3 and 10 previously reported to be associated with familial hypobetalipoproteinemia,6,7 nor for any other regions in the genome."
    explanation: Independently corroborates that FHBL families exist that map to loci other than APOB, PCSK9, or ANGPTL3.
  proposed_experiments:
  - experiment_id: fhbl_3p21_positional_cloning
    name: Positional cloning / whole-genome sequencing of chromosome 3p21-linked FHBL families
    description: >-
      Apply whole-genome or long-read sequencing to pedigrees with linkage to
      chromosome 3p21 (and to families linked to neither APOB nor 3p21) to
      identify the causal gene(s) and determine whether they act by a
      production-limiting, clearance-enhancing, or novel mechanism.
references:
- reference: PMID:33983694
  title: "APOB-Related Familial Hypobetalipoproteinemia."
  tags:
  - GeneReviews
- reference: PMID:37471510
  title: "Familial Combined Hypolipidemia."
  tags:
  - GeneReviews
- reference: PMID:15654334
  title: "Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9."
- reference: PMID:16554528
  title: "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease."
- reference: PMID:20942659
  title: "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia."
- reference: PMID:24751931
  title: "Hypobetalipoproteinemia and abetalipoproteinemia."
- reference: PMID:28385496
  title: "ANGPTL3 Deficiency and Protection Against Coronary Artery Disease."
- reference: PMID:32039990
  title: "Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease."
- reference: PMID:32813947
  title: "Evinacumab for Homozygous Familial Hypercholesterolemia."
- reference: PMID:28304224
  title: "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease."
- reference: PMID:24288038
  title: "Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management."
- reference: PMID:15818469
  title: "Familial hypobetalipoproteinemia: genetics and metabolism."
- reference: PMID:13130124
  title: "Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele."
- reference: PMID:38710625
  title: "Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1."
- reference: PMID:41473260
  title: "Current and Emerging Issues in Familial Hypobetalipoproteinemia-related Steatotic Liver Diseases."
- reference: PMID:34564380
  title: "Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families."
review_notes: >-
  Created 2026-08 in response to issue #9548 (CURATE_ROOT_WITH_SUBTYPES).
  Models the apoB-dosage/clearance axis of hypobetalipoproteinemia across
  three mechanistically distinct genetic causes (APOB, PCSK9, ANGPTL3),
  deliberately distinguished from the MTTP-lipidation mechanism of
  Abetalipoproteinemia.yaml and from the ligand-gain-of-function mechanism of
  Familial_Defective_Apolipoprotein_B-100.yaml. PCSK9-inhibitor and
  ANGPTL3-inhibitor treatments are curated as the therapeutic validation of
  this entry's human-genetics rationale rather than as treatments for
  hypobetalipoproteinemia itself, which is generally benign in its PCSK9 and
  ANGPTL3 forms. The ANGPTL3-to-LDL-cholesterol mechanism is explicitly
  marked PROVISIONAL, since Musunuru et al. (PMID:20942659) state the
  LPL/endothelial-lipase mechanism explains the triglyceride/HDL phenotypes
  but not the LDL phenotype, whose mechanism "remains to be determined."
clinical_trials: []
datasets: []

📚

References & Deep Research